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Exosomes are a class of extracellular vesicles that have been shown to contribute to 
metastasis when derived from tumor cells.  Myeloid-derived suppressor cells 
(MDSC) are an immature population of myeloid cells that accumulate in the tumor 
microenvironment and inhibit anti-tumor immunity. Given the role of the source 
cells, it is our hypothesis that MDSC-derived exosomes may contribute to or mediate 
the effects of MDSC in the tumor microenvironment.  The goal of this work is to use 
mass-spectrometry based proteomics to characterize exosomes produced by MDSC 
that are induced by 4T1 mammary carcinoma.  The protein content of the exosomes 
will be analyzed to determine if the exosomal proteome is representative of the 
parental cells or if it reflects active protein sorting.   
 Increased inflammation in the tumor microenvironment is associated with an 
increased population of MDSC, which further increases the level of immune 
suppression.  Here, the relative change in abundance of exosomal proteins under a 
  
heightened level of inflammation in the tumor microenvironment will be performed 
using the spectral count method.   
 While it is known that exosomes first form through invagination at the plasma 
membrane, the mechanism(s) through which the protein cargo is sorted into exosomes 
remains poorly understood. Given the role of ubiquitination in protein localization 
and trafficking, immunoaffinity enrichment coupled to mass spectrometry has been 
employed to identify exosomal proteins that carry this modification.  Identification of 
the substrate proteins in MDSC-derived exosomes may provide insight into exosome 
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Chapter 1: Introduction 
 
Research Significance and Objectives 
The role of a class of extracellular vesicles, termed exosomes, in the tumor 
microenvironment is currently an active area of research.  Multiple reports have 
demonstrated that tumor cell-derived exosomes are composed of soluble factors and 
genetic material that contribute to metastasis.1 However, the composition and 
function of exosomes is expected to reflect that of the parent cell.2  The tumor 
microenvironment is composed of many cells that contribute to tumor-induced 
immune suppression, in addition to tumor cells; therefore, it is our interest to 
investigate the role of exosomes derived from myeloid derived suppressor cells 
(MDSC) in intercellular communication in the tumor microenvironment. 
MDSC are immature myeloid cells that accumulate in the tumor 
microenvironment and are present in tumor bearing mice as well as patients with 
advanced cancer.3-5 MDSC inhibit anti-tumor immunity through suppression of T cell 
activation and polarization of macrophages towards a tumor promoting phenotype.6, 7 
Furthermore, increased inflammation in vivo is associated with increased 
accumulation of MDSC in the tumor microenvironment, which propagates immune 
suppression.8, 9 Several mechanisms of MDSC activity have been associated with 
suppression of T cell activation, some of which require cell-to-cell contact.8-10  It is 




the immune suppressive activity and accumulation of MDSC in the tumor 
microenvironment. 
 MDSC produce extracellular vesicles that have all the characteristics11-13 of 
exosomes. Electron microscopy experiments by Johnstone and coworkers, who 
contributed to the discovery of exosomes, have shown that exosomes are formed via 
invagination of the limiting membrane to form endosomes, which invaginate further 
to form multivesicular bodies.  The multivesicular body fuses with the plasma 
membrane to release its contents into the extracellular milieu, which are then termed 
exosomes.14, 15 MDSC-derived exosomes used in this work have been provided by Dr. 
Suzanne Ostrand-Rosenberg.16 Here, mass spectrometry-based proteomics is used to 
identify the protein cargo of exosomes from MDSC induced by 4T1 mammary 
carcinoma (termed “conventional”) and 4T1 cells transfected with and expressing 
interleukin-1β (termed “inflammatory”).  Due to the increased suppressive potency of 
MDSC under heightened inflammatory conditions, quantitative mass spectrometry is 
also employed to compare protein abundances in exosomes from conventional and 
inflammatory MDSC. 
 Ubiquitination has been shown to signal both the internalization of surface 
proteins and the sorting of proteins into endosomal proteins; both have been proposed 
as possible mechanisms of exosome biogenesis.17-20 We utilize immunoaffinity 
enrichment coupled to tandem mass spectrometry to identify ubiquitinated proteins 
present in exosomes shed by inflammatory MDSC.21 Biological assays have 
demonstrated that MDSC-derived exosomes carry proinflammatory proteins that 




tumor promoting phenotype.16 Therefore, it is of interest to the community to 
investigate the nature of the protein cargos of exosomes. The presence of 
ubiquitinated proteins in exosomes has been previously reported using western blot 
analyses22; however, the conjugated proteins were not identified.   
Ubiquitin is an 8.5 kDa protein that forms an isopeptide bond though its 
terminal Gly76 and an ε-amino group of a lysine in a substrate protein or another 
ubiquitin, which contains seven lysine residues (Lys6, 11, 27, 29, 33, 48, and 63).  
One of the multiple tryptic cleavage sites in ubiquitin is Arg74, which leaves Gly75 
and Gly76 on the modified lysine of a substrate protein or an additional ubiquitin 
moiety.23-25 This ubiquitin remnant can be identified through tandem mass 
spectrometry and bioinformatics analysis. Here, bottom up proteomic techniques are 
used to identify exosomal peptides that contain a glycinylglycine-modified lysine 
residue.  Moreover, Gene Ontology annotations and the UniProt database will be used 
to look for trends in the cellular location (relative to the parental cell), protein 
function, size, and pI values of the ubiquitinated proteins.  This may provide insight 
into the role of ubiquitination in exosome formation and/or function. 
 
Myeloid-Derived Suppressor Cells 
 Chronic inflammation and cancer are associated with an increase in a 
population of immature myeloid cells.4 Activation by pro-inflammatory factors, such 
as interleukin-6 (IL-6) and interleukin-1 (IL-1β), inhibit the differentiation of the 
immature myeloid cell population, termed myeloid-derived suppressor cells (MDSC). 




microenvironment.7 Under healthy conditions, myeloid cells from the bone marrow 
would differentiate into dendritic cells, macrophages, and/or granulocytes; however, 
the immature MDSC population that accumulates upon activation inhibits both innate 
and adaptive immunity and promotes tumor progression in the tumor 
microenvironment.6, 26   
 Under normal conditions, immature myeloid cells make up approximately 
0.5% of mononuclear cells in the blood. However, a ten-fold increase in MDSC has 
been observed in cancer patients.4, 27-29 The role of MDSC in promoting tumor 
progression inhibits successful immunotherapy in cancer patients.30 The causal 
relationship between chronic inflammation and tumor progression was first proposed 
by Virchow in the 1800’s; however, the mechanism(s) that mediate this relationship 
are not completely understood.8 Therefore, a reduction in inflammation prior to 
immunotherapy has been proposed to improve the outcome of immunotherapy.9 
 MDSC skew the immune response and promote tumor progression through 
multiple activities including the induction of T regulatory cells and polarizing 
macrophages towards a tumor promoting phenotype.31-33 MDSC production of 
interleukin-10 (IL-10) down-regulates macrophage production of interleukin-12 (IL-
12) and skews macrophages from a tumoricidal phenotype to that of a tumor 
promoting M2-like phenotype. 32,33 Additional mechanisms of MDSC activity include 
production of arginase 6,8,10,32,34,35 and inducible nitric oxide synthase 6, 36,37.  
 In addition to the pro-inflammatory factors produced by tumor cells, MDSC 
produce S100 A8 and A9, which are calcium-binding proteins that belong to the S100 




heterodimer that promotes MDSC accumulation in the tumor microenvironment.4 In 
addition to producing the dimer, MDSC contain the N-glycan receptors for 
S100A8/A9 on their surface, which creates an autocrine feedback loop that ensures 
accumulation of MDSC in the tumor microenvironment and increased immune 
suppression.38 
Exosomes 
 Extracellular vesicles produced by cells include shedding microvesicles, 
apoptotic bodies and exosomes.1, 39 Exosomes differ from microvesicles and apoptotic 
bodies in their size, sucrose density and composition (protein, lipid, and nucleic 
acids).1 Extracellular vesicles were originally observed from cartilage in 1969.40 
However, in 1983 the exosomal biogenesis pathway was described (Figure 1).14, 41 
Exosomes are membrane-bound vesicles that are first formed through invagination at 
the plasma membrane to form early endosomes and mature to form intraluminal 
vesicles (Figure 1 a and b, respectively).15  Further budding of the endosomal 
membrane generates multivesicular bodies that can either fuse with lysosomes for 
degradation or fuse with the plasma membrane to exocytose their contents into the 
extracellular space (Figure 1 c).15 Exosomes are reported as 30-100 nm in diameter 
and contain marker proteins including heat shock protein 70, Alix [ALG-2 (apoptosis-
linked gene 2)-interacting protein X], Tsg101 (tumor suppressor gene 101), and 










Figure 1. Exosome biogenesis. 15 
 
  More recently, a report demonstrated that exosomes derived from Epstein-
Barr virus transformed B cells contain major histocompatibility complex (MHC) class 
II molecules 43 and suggested that exosomes may participate in intercellular 
communication.44 Additionally, exosomes have been shown to promote angiogenesis, 
induce T regulatory cells, suppress natural killer cells, and inhibit DC maturation.45, 46 
Together, these functions suggest that exosomes may promote metastasis via the 
formation of a pre-metastatic niche.46, 47, 48 
 Exosomes can be purified from the parent cells and other contaminating 
vesicles present in cell culture through differential centrifugation.43, 49, 50 Relatively 
low speed centrifugations at 300, 200, and 10,000 x g are first performed to eliminate 
cells, cellular debris, and large extracellular vesicles (greater than 100 nm in 
diameter).50 Ultracentrifugation at 100,000 x g is then performed on the supernatant 







density gradient can be used to further purify the exosomes, since the vesicles are 
expected to band in the gradient and protein aggregates are expected to sediment.43, 50, 
51 Together, differential centrifugation and transmission electron microscopy, used to 
characterize vesicle size and morphology, are considered the gold-standard of 
exosome purification.43, 44 More recently, the use of filtration and purification of 
exosomes based on classical exosome marker proteins have been increasingly used to 
obtain exosomes; however, the possibility of variability in the exosomes obtained 
from these methods has not been verified.12  
 While the biogenesis of exosomes has been reported, 14, 41 the exact 
mechanism of endosomal sorting of protein, lipid, and nucleic acids into exosomes 
remains unclear.  Proteins belonging to the endosomal-sorting complex required for 
transport (ECSRT) have been identified in exosomes (Alix and Tsg101).  Moreover, 
the exosomal marker proteins CD63 and CD81 have been found to co-purify with the 
ESCRT protein vacuolar sorting protein 4B (VPS4B) following exosome 
purification.52 The ESCRT pathway is known to participate in intraluminal vesicle 
and multivesicular body formation.53 It comprises 20 proteins, which make up four 
complexes.  ESCRT-0 protein complex recognizes and traffics ubiquitinated proteins 
in the endosomal membrane, which is followed by membrane deformation by the 
ESCRT-1 and –II complexes.  The ESCRT-III complex participates in membrane 
scission, releasing the intraluminal vesicle.54, 55 Due to the overlap in endosomal and 
exosomal formation, including intraluminal vesicles and multivesicular bodies, it has 
been highly speculated that the ESCRT may participate in protein trafficking into 




and VPS4B) does not completely abolish multivesicular body formation.56 This 
suggests that perhaps only part of the ESCRT pathway participates in exosome 
formation and/or other mechanisms may also participate in the protein sorting and 
vesicle formation.53 
 Additional mechanisms that have been reported to affect exosome formation 
and/or release include high luminal concentration of calcium and higher-order 
oligomerization of plasma membrane proteins.57, 44 An increase in luminal calcium 
concentration has been shown to increase exosome production in erythroleukemia cell 
line K562, 58 oligodendroglial cells, 59 dendritic cells 60 and mast cells.61 Additionally, 
higher-order oligomerization has been shown to target plasma membrane proteins to 
exosomes.57  This result is consistent with the original work on exosome formation in 
maturing reticulocytes, in which aggregation of the transferrin receptor corresponds 
to sites of exosome formation.57, 62 Interestingly, unlike an ESCRT-dependent 
formation, higher order oligomerization is independent of protein sequence and 
function.57  Collectively, in addition to the potential role of the ESCRT pathway in 
exosome formation, evidence suggests that the luminal calcium concentration and 
higher-order oligomerization may also participate in the formation of intraluminal 
vesicles and multivesicular bodies that exocytose their contents into the extracellular 
space.  
 In addition to studying the mechanisms of protein trafficking into exosomes, 
another active area of research includes the RNA that is sorted into exosomes.  In 
2007, Valadi and coworkers reported the presence of messenger RNA (mRNA) and 




from mice were able to transfer functional mRNA to human cells.44 Since 2007, 
additional reports have demonstrated the presence of ribosomal RNA, mRNA, and 
noncoding RNAs including miRNA.64 Due to previous observations that exosomes 
may mediate communication in the tumor microenvironment through chemokines and 
growth factors, 64 a new question is raised whether exchange of genetic material 
(miRNA) may also contribute to metastasis.65-67 
 Due to the promising role of exosomes in intercellular communication, 
another area of active research is the use of exosomes in clinical research.  Exosomes 
are considered a promising candidate for clinical use due to their stability in 
circulation64, 68 and a protein cargo that impedes exosome degradation.69 Recently, 
mesenchymal stem cell-derived exosomes have been shown to reduce infarct size in 
mice.64 Additionally, extracellular vesicle-based cancer vaccines are currently being 
evaluated in Phase I clinical trials and dendritic cell-derived extracellular vesicles will 
be evaluated for non-small-cell lung cancer in Phase II clinical trials.64, 70 While the 
application of exosomes as cancer vaccines is promising, much still remains to be 









Chapter 2: Comparative Exploration of Exosomes from 
Tumor-Induced Immune Suppressive Myeloid-Derived 




In order for tumors to establish metastasis, tumor cells must evade the 
immune system.46,47 Myeloid-derived suppressor cells have previously been shown to 
promote tumor growth through suppression of T cell activation and polarization of 
macrophages towards a tumor promoting phenotype.6,7 However, exosomes have also 
demonstrated potential to contribute to metastasis through their ability to transfer 
proteins and RNA to recipient cells.46, 71 Moreover, the ability of tumor cells to thrive 
is dependent upon communication between the tumor cells and the neighboring tissue 
and extracellular matrix.71 It is possible that, in addition to tumor cell-derived 
exosomes, exosomes produced by cells present in the tumor microenvironment, such 
as MDSC, may contribute to tumor growth and metastasis.  Tumor cell-derived 
exosomes in a mouse glioblastoma xenograft model have been shown to promote 
tumor growth.72 Therefore, it is our goal to determine how exosomes derived from 
MDSC may also contribute to tumor growth in BALB/c mice carrying 4T1 mammary 
carcinoma using mass spectrometry-based proteomics. 
 As discussed earlier, increased inflammation is associated with an increase in 
MDSC accumulation and thereby increased immune suppression.8,9 However, the 




understood.8 It has been shown that MDSC activity requires cell-to-cell contact 
and/or soluble mediators.8-10 It is our hypothesis that MDSC-derived exosomes may 
contribute to MDSC accumulation and immune suppression in the tumor 
microenvironment through mediating intercellular communication.  Therefore, the 
identification of MDSC-derived exosomal proteins whose abundance is significantly 
altered due to heightened inflammation is expected to provide insight into the role of 
exosomes in the tumor microenvironment. 
Mass spectrometry-based proteomics is ideal for investigating the role of 
exosomes in the tumor microenvironment as proteins participate in most clinical 
conditions.73 Additionally, changes in protein abundance do not correlate with mRNA 
abundance.74,75 In order to compare the effect of heightened inflammation on protein 
abundance, available quantitation methods include stable isotope labeling (either 
metabolic or chemical tags) and label-free quantitation, which utilizes peptide 
precursor ion intensity or spectral counts.74 It is believed that isotopic-labeling 
methods provide more accuracy, while label-free methods offer greater proteome 
coverage.74 In this study, the spectral count method has been used to identify proteins 
with altered abundance under heightened inflammatory conditions.   
The spectral count method is based on the assumption that the frequency at 
which a precursor peptide is selected for fragmentation correlates to the peptide, and 
therefore protein, abundance. The spectral count method requires that care is taken to 
avoid assigning identified peptides to multiple proteins, which would significantly 
alter peptide and protein quantitation.74 Therefore, we have chosen to calculate 




contain at least two distinct, unshared peptides and each unique peptide is assigned to 
only one protein. 
Here, mass spectrometry-based proteomics followed by spectral count 
quantitation is used to identify differentially abundant exosomal proteins due to 
heightened inflammation in the tumor microenvironment.  The results from this 
analysis will allow us to ask if the exosomal proteins identified reflect the known 
immunosuppressive function of the source cells, MDSC.  Moreover, is it possible that 
the MDSC-derived exosomes can contribute to this activity in the tumor 
microenvironment?  If so, this would provide evidence that the role of exosomes in 
the tumor microenvironment should be considered as potential obstacles to 
immunotherapy. 
Materials and Methods 
 
Myeloid-Derived Suppressor Cells  
 BALB/c mice were injected in the mammary fat pad with 7000 wild type 4T1 
mammary carcinoma cells or 4T1 cells stably transfected and expressing IL-1β as 
described.  When tumors were greater than ~8mm in diameter (~3-4 weeks after 
initial inoculation), MDSC were harvested from the blood and monitored by 
immunofluorescence and flow cytometry for purity by expression of the MDSC 
markers Gr1 and CD11b (Figure 2).8 MDSC used in experiments were >90% 
Gr1+CD11b+. MDSC induced by wild type 4T1 and 4T1/IL-1β tumor cells are termed 
“conventional” and “inflammatory” MDSC, respectively.  All procedures with 
animals and animal-derived materials were approved by the UMBC and UMCP 





Figure 2: A: Flow cytometry profile of MDSC expression for Gr1 and CD11b. B: 
Sucrose density (g/mL) and optical density (OD 280) plots of fractions from sucrose 
density gradients containing exosomes from conventional (left) and inflammatory 
(right) MDSC.             
 Exosomes 
 Purified MDSC obtained from 2 or 3 mice (~1 x 108 MDSC for each 
experiment) were plated at 4 x 106 cells/mL in serum-free HL-1 medium 
(BioWhittaker, Walkersville, MD) and maintained at 37 °C with 5% CO2. After 16 
hours the cultures were centrifuged at 805 x g for 5 min (Eppendorf 5810R 
centrifuge), the pellets discarded, and the supernatants centrifuged at 2090 x g for 30 
min (Sorvall RC5C, SS34 rotor).  The supernatants were then ultracentrifuged 




rotor.  Supernatants were discarded, the pellets containing the exosomes were 
resuspended in PBS, and absorbances were measured at 260 and 280 nm.  Protein 
content was assayed by Bradford Quick Start according to the manufacturer’s 
directions (BioRad). Exosomes were stored at -80 °C until used.  For migration 
experiments, exosomes were resuspended to the original volume of the conditioned 
medium from which they were obtained so a direct comparison of the effects of 
exosomes versus conditioned medium could be made.  For the MDSC-macrophage 
cross-talk experiments, exosomes were used at 1x, 2.5x, and 5x concentrations.  On 
average, 1 mL of conditioned medium contained 714 µg of exosomal protein. 
 Sucrose Density Gradient Fractionation of Exosomes 
 Freshly prepared ultracentrifuged exosomes were resuspended in 1.8-2.0 mL 
of 2.5 M sucrose/0.020 M Hepes and layered on the bottom of 9/16 in. x 3 ¾ in. 
polyallomer ultracentrifuge tubes (Beckman). A 10 mL gradient of 0.25 to 2.0 M 
sucrose in 0.020 M Hepes was then layered over the 2 mL containing exosomes for a 
total volume of 11.8-12 mL. Gradients were ultracentrifuged (Beckman L8 
ultracentrifuge) at 10 °C for 16 hours at 100,000 x g in an SW40Ti rotor.  Then, 0.5 
mL fractions were collected and assessed by optical density (Figure 2).  Density of 
the fractions was confirmed by refractometry. 
 Transmission Electron Micrographs 
 An aliquot of exosomes containing 0.03-0.3 pg total protein was suspended in 
2% glutaraldehyde and was applied to a Formvar-coated grid and negatively stained 
with uranyl acetate. Electron micrographs were acquired using a Zeiss EM10 




 Protein Analysis for In-solution Tryptic Digestion 
 Aliquots of conventional and inflammatory exosomes containing 25 µg of 
total protein were lysed in 8 M urea in 50 mM ammonium bicarbonate and 1% of a 
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO).  The exosomes in lysis 
buffer were centrifuged at 14,000 x g for 30 minutes with a 3 kDa molecular weight 
cutoff filter, and the supernatants were discarded. The process was repeated three 
times with the retentate from the previous wash step.  After lysis, fifty millimolar 
ammonium bicarbonate was added to each sample to dilute the final urea 
concentration to >0.8 M, which is compatible with tryptic digestion.  Each sample 
was then reduced in 20 mM dithiothreitol at 56 °C for 30 minutes followed by 
alkylation in 40 mM iodoacetamide at room temperature in the dark for 30 minutes.  
Three technical replicates of 7 µg total protein were analyzed by LC-MS/MS (using 
HPLC-MS/MS parameters outlined below) for three biological replicates each for 
conventional and inflammatory exosomes. 
 HPLC-MS/MS Analysis 
 LC-MS/MS analyses were performed on a Shimadzu Prominent nanoHPLC 
(Shimadzu BioSciences, Columbia, MD) in-line with an LTQ Orbitrap XL (Thermo 
Fisher Scientific, San Jose, CA). Peptides prepared via tryptic digestion were injected 
onto an Acclaim PepMap 300 C18 precolumn (Dionex, Sunnyvale, CA) followed by 
desalting by 10% Solvent A (97.5% H2O, 2.5% ACN, and 0.1% formic acid) for 20 
minutes. Peptides were fractionated on a C-18 analytical column (Grace Vydak, 
Deerfield, IL) with a linear gradient increasing from 0 to 40% solvent B (97.5% 




from 40% to 85% solvent B in 40 minutes.  Flow rate was 500 nL/min. Precursor 
scans were acquired in the orbitrap with a resolution of 30,000 at m/z 400. In each 
cycle the nine most abundant ions were selected for fragmentation by collisional 
induced dissociation (CID), and product ion scans were acquired in the LTQ. A 
dynamic exclusion of 1 repeat count over 180 seconds was used. 
 Bioinformatics 
 Peptides and proteins were identified by the PepArML meta-search engine76 
using the mouse reference proteome of the UniProtKnowledgeBase (June 2013) 
containing 50,807 sequences.  Carbamidomethylation of cysteine was selected as a 
fixed modification, and oxidation of methionine and deamidation of asparagine and 
glutamine residues were selected as variable modifications. Peptide identifications 
from technical and biological replicates were pooled and filtered at 1% spectral FDR, 
as computed by PepArML using the method of Elias and Gygi, 77 and identified 
proteins were required to contain at least two distinct, unshared peptides, ensuring 
protein FDR of at most 0.01%.  Spectral counts for identified proteins, spectral count 
ratios (Rsc) as described in Old et al., 78 and statistical significance for differential 
spectral counts were determined using in house software.  Differential spectral count 
p-values were computed using the Fisher exact-test and corrected for multiple testing 
by transformation to false-discovery-rate (FDR) using the method of Benjamini and 
Hochberg.79 Identified proteins are assigned to cellular components according to their 
Gene Ontology annotations and the PIR GO Slim. 




 Cells used in the chemotaxis assay were >90% Gr1+CD11b+ conventional 
MDSC as assessed by flow cytometry.35 Five hundred microliters of fresh media, 
media from MDSC cultures (conditioned media), or MDSC-derived exosomes from 
the equivalent amount of conditioned medium in fresh media were placed in 
individual wells of 24-well plates (lower compartment). Monoclonal antibodies to 
S100A8, S100A9, or irrelevant control isotype matched antibodies (10 µg/500 µL; 
Santa Cruz Biotech) were included in some wells.  Transwells with an 8 µm 
polycarbonate semipermeable membrane were then inserted in each well, and 1x106 
MDSC in 100 µL of serum-free IMDM medium were placed in the transwells (upper 
compartment).  Assembled transwells were incubated at 37 °C in 5% CO2 for 3 hours, 
and the MDSC in the bottom chamber were then quantified by hemocytometer. 
Values for each sample are the average results of duplicate samples and three 
independent hemocytometer counts per well.38 
 MDSC-Macrophage Cross-Talk 
 BALB/c mice were injected intraperitoneally with 1 mL of 3% thioglycolate, 
and peritoneal exudate cells (PEC) were harvested 4 days later.  The percent of 
macrophages in the exudate was determined by flow cytometry analysis of the 
macrophage markers F4/80 and CD11b. PEC were plated in 24-well plates at 7.5 x 
105 F4/80+CD11b+ cells/well/500 µL DMEM medium supplemented with 10% fetal 
bovine serum and incubated at 37 °C in 5% CO2 for 3 hours. Non-adherent cells 
(non-macrophages) were then removed, and the attached macrophages were washed 
with macrophage medium (DMEM/5% serum). Five hundred microliters of 




cells) or MDSC-derived exosomes from 7.5x105 (1X), 18.7x105 (2.5X), or 37.5x105 
(5X) MDSC were then added to each well.  MDSC and macrophages were activated 
with IFNγ and LPS and co-cultured at a ratio of 1:1 (5x105 cells of each type/200 
µL/well) for 18 hours.  Supernatants were harvested and assayed by ELISA for 
interleukin-12 (IL-12).9 
Results and Discussion 
Cells produce several types of extracellular vesicles including exosomes, 
shedding microvesicles, and apoptotic bodies.  Differential centrifugation is used to 
separate exosomes from their parental cells as well as larger extracellular vesicles 
(greater than 100 nm in diameter).  However, further characterization is required in 
order to determine if the purified extracellular vesicles meet the criteria of 
exosomes.43 After sucrose density gradient purification, MDSC-derived exosomes, 
prepared by Dr. Suzanne Ostrand-Rosenberg’s laboratory at the University of 
Maryland Baltimore County, were further characterized using transmission electron 
microscopy.  The purified MDSC-derived vesicles from both conventional and 
inflammatory MDSC equilibrate at a sucrose density of 1.2-1.3 g/mL (Figure 2) and 
are approximately 25-30 nm in diameter (Figure 3).  The transmission electron 
micrograph images of both conventional and inflammatory exosomes reveal vesicles 
of similar diameter and morphology.  The control grid shown in Figure 3 prevents the 
15 nm artifacts from the negative staining from being considered as vesicles.  
Together, the sucrose density and diameter of the vesicles is consistent with the 





Figure 3: Transmission electron microscope images of (left) exosomes shed by 
conventional MDSC; (middle) exosomes shed by inflammatory MDSC; the TEM 
stain itself (right). 
 
 In order to compare the amount of exosomes produced by conventional and 
inflammatory MDSC, the total amount of exosomal protein was normalized for the 
number of MDSC cells used in each preparation.    The amount of exosomes 
produced per cell, expressed as the amount of exosomal protein (µg) per MDSC cell, 
was [1.1 ± 0.1] x 10-6 (n=4) and [1.2 ± 0.2] x 10-6 (n=4) for conventional and 
inflammatory MDSC, respectively.  The similar ratios demonstrate that conventional 
and inflammatory MDSC produce the same amount of exosomes on a per cell basis. 
 Next, mass spectrometry-based proteomics was used to identify peptides, and 
therefore proteins, present in conventional and inflammatory exosomes from three 
biological replicates, each with three technical replicates.  Three hundred and eighty 
seven proteins were identified  (from 2528 peptides) in exosomes from conventional 
MDSC (Appendix Table 1), and 374 proteins were identified (from 2280 peptides) in 
exosomes from inflammatory MDSC (Appendix Table 1).  Together, a total of 412 




This inventory was compared with several databases of exosomal proteins in order to 
evaluate the number of proteins in MDSC-derived exosomes that have been 
previously reported in exosomes from other cell types.  ExoCarta was the first 
exosomal database established by Mathivanan and Simpson.81 Approximately 83% of 
the proteins identified in MDSC-derived exosomes are present in the ExoCarta 
compendium (August 2013).  Another resource is EVpedia, which was developed by 
Kim et al.82 Approximately 87% of the proteins identified in MDSC-derived 
exosomes have been reported in EVpedia (August 2013).  Lastly, Kalra and 
Mathivanan et al. have also developed a compendium for proteins from all types of 
extracellular vesicles, called Vesiclepedia.83 When compared to the general database 
of vesicular proteins, about 93% of the proteins identified in MDSC-derived 
exosomes are also present in Vesiclepedia.  Proteins identified in MDSC-derived 
exosomes that have not previously been reported in ExoCarta, EVpedia, or 
Vesiclepedia are listed in Appendix Table 2.  
 Among the inventory of 412 exosomal proteins identified in this study, several 
proteins considered to be characteristic of exosomes were observed.  These proteins 
include annexins (A1, A2, A3, A6, A7, A11) and tetraspanins, including CD177 as 
well as GTPases, NCK microfibrils (NCK associated protein 1 like), heat shock 
proteins (heat shock cognate 71 kDa protein, heat shock 70 kDa protein 4, and HSP90 
alpha and beta) and cytoskeletal proteins.  Another protein of interest includes 
vacuolar-sorting protein 35 (VPS35), which is a member of the endosomal sorting 
complex required for transport.  This pathway has been proposed to play a role in 




 Additional proteins of interest identified in MDSC-derived exosomes include 
several proteins belonging to the 26S proteasome.  These proteins include 26S 
protease regulatory subunit 6A, 26S proteasome non-ATPase regulatory subunits 1, 2, 
5, 6, 7, 11, and 13, proteasome subunit beta type-2, and proteasome subunit alpha 
type-6.  Proteasomal subunits have also been observed in extracellular vesicles 
produced by T lymphocytes and have been shows to be proteolytically active.84 
 Interestingly, more than a dozen histones were identified in MDSC-derived 
exosomes as well as several elongation factors (1-gamma, 1-alpha 1 and 2), DNA 
topoisomerase, RNA helicase (ATP-dependent RNA helicase DDX39A) and a zinc 
finder protein (DBF-type zinc finger-containing protein 2 homologue).  Recently, the 
high abundance of histones and other transcription-related proteins has gained 
attention from the exosome community.85 It has been proposed that the transcription 
factors present in exosomes may alter signaling pathways in a way that enables 
disease progression or tumor growth or that perhaps the presence of nucleic acid 
binding proteins is required to allow the nucleic acids to fit within the limited space 
of exosomes.85 The high abundance of histones and nucleic acid binding proteins in 
exosomes from various cell types highlights the need for further investigation of 
nucleic acid binding proteins in exosomes. 
 Several metabolic proteins have also been identified in MDSC-derived 
exosomes belonging to the pentose phosphate pathway.  These proteins include 
glucose-6-phosphate 1-dehydrogenase X, 6-phosphogluconate dehydrogenase, and 
transketolase.  Additionally, several proteins belonging to the glycolysis and 




phosphate isomerase, glyceraldehyde-3-phosphate dehydrogenase, alpha-enolase, L-
lactate dehydrogenase A chain, fructose-bisphosphate aldolase, phosphoglycerate 
kinase 1, glycogen phosphorylase liver form, and glycogenin-1).  These metabolic 
proteins have also been reported in exosomes derived from other cell types and are 
present in the exosomal databases.81-83 
 In addition to proteins previously observed in exosomes, proteins were 
identified in MDSC-derived exosomes that are critical for MDSC function and the 
proinflammatory response.  Proteins S100A8 and S100A9 have been identified in 
MDSC-derived exosomes and are known to drive MDSC accumulation and immune 
suppression in the tumor microenvironment.38, 86 Additionally, myeloid bactenecin 
was identified, which has previously been reported to interact with immune cells and 
participate in the inflammatory response.87 
 In order to determine if the exosomal cargo of exosomes is representative of 
the parent cell or enriched for a subset of proteins, the cellular component GO 
annotations for the protein identifications for the conventional and inflammatory 
exosomes were compared to those belonging to 305 proteins identified in whole cell 
lysate analysis of conventional MDSC.88 The cellular component GO annotations 
ascribed to exosomal proteins are relative to the parent cell, MDSC, as the exosomes 
do not contain organelles.  The distribution of cellular component GO annotations for 
conventional and inflammatory exosomes shown in Figure 4 illustrates that the 
protein content of the exosomes is similar.  When the conventional and inflammatory 
exosomes are compared to the conventional MDSC, the distribution is similar with 




contain a greater abundance of nuclear proteins, including the histones and 
transcription factors described earlier. 
  
 
Figure 4: Intracellular protein locations assigned by Gene Ontology annotations and 
the PIR GO Slim.  Green: from exosomes from conventional MDSC; Red:  from 
exosomes from inflammatory MDSC; Blue: from lysate88 of conventional MDSC. 
 
 While the protein content of the conventional and inflammatory exosomes is 
similar, the spectral count method was used to determine how heightened 
inflammation in the tumor microenvironment alters protein abundance in the 




conventional and inflammatory exosomes were found to differ in abundance by two 
fold or more (FDR ≤0.05).  From the cohort of 63 proteins with altered protein 
abundance, 33 were found to decrease by at least two fold under heightened 
inflammatory conditions (Table 1).   Several of the proteins with decreased 
abundance participate in the innate immune response including ficolin-1, C4b-binding 
protein, Chitinase-3-like protein 3, complement C3, and CD5 antigen-like proteins.  
Additional proteins of interest include cytoskeletal proteins spectrin beta 1, ankyrin-1, 
tubulin beta-1 chain, and nesprin-1.  Ankyrins anchor transmembrane proteins and 
link them to the spectrin-actin cytoskeleton and participate in cell motility and 
intercellular communication.89,90 Chemotactic proteins with decreased abundance 
include myeloid cysteine-rich protein and platelet factor 4.   Together, the decrease in 
cytoskeletal and chemotactic proteins make it tempting to speculate that inflammation 
may alter proteins that participate in intercellular communication. 
 
Table 1: Proteins with significantly greater abundance in conventional exosomes (Rsc 
≥1 and FDR ≤0.05). Rsc is reported as the log2 ratio of conventional versus 
inflammatory exosomes. 
Accession Protein RSC FDR 
P70390 Short stature homeobox protein 2 8.6 6.26E-157 
P04919 Band 3 anion transport protein 6.4 5.05E-32 
P08032 Spectrin alpha chain, erythrocytic 1 5.6 7.16E-19 
Q8CIZ8 von Willebrand factor 4.8 3.56E-10 
P08226 Apolipoprotein E 4.6 5.86E-09 




Q9QUM0 Integrin alpha-IIb 4.3 6.14E-07 
P01837 Ig kappa chain C region 3.7 1.28E-04 
P29788 Vitronectin 3.3 1.50E-03 
P49722 Proteasome subunit alpha type-2 3.3 1.50E-03 
Q02357 Ankyrin-1 3.3 1.50E-03 
Q3UGX2 Spectrin beta 1 3.3 1.50E-03 
Q8K482 EMILIN-2 3.3 1.50E-03 
Q9QWK4 CD5 antigen-like 3.0 9.63E-03 
Q07797 Galectin-3-binding protein 2.8 1.74E-02 
P11276 Fibronectin 2.7 3.08E-124 
O70165 Ficolin-1 2.7 2.95E-02 
P08607 C4b-binding protein 2.6 4.68E-03 
P10605 Cathepsin B 2.5 8.26E-03 
P07724 Serum albumin 2.5 7.87E-22 
Q61646 Haptoglobin 2.1 1.08E-03 
P01942 Hemoglobin subunit alpha 2.1 9.53E-47 
P01872 Ig mu chain C region secreted form 2.1 7.19E-13 
O35744 Chitinase-3-like protein 3 2.0 8.90E-05 
P35441 Thrombospondin-1 1.9 4.55E-14 
Q6ZWR6 Nesprin-1 1.9 1.54E-02 
P62259 14-3-3 protein epsilon 1.5 6.12E-03 
P82198 Transforming growth factor-beta-induced protein ig-
h3 
1.5 1.04E-02 
Q8C2Q7 Heterogeneous nuclear ribonucleoprotein H 1.5 4.89E-02 
A2AQ07 Tubulin beta-1 chain 1.5 1.88E-03 
P02089 Hemoglobin subunit beta-2 1.4 2.67E-10 




P02088 Hemoglobin subunit beta-1 1.3 5.26E-15 
Q8K426 Myeloid cysteine-rich protein 1.3 2.59E-02 
Q9Z126 Platelet factor 4 1.1 4.71E-03 
Q9R1P3 Proteasome subunit beta type-2 1.0 2.41E-02 
 
 Thirty exosomal proteins were found to increase in abundance (Table 2) due 
to heightened inflammation.  Several GTP and ATP binding proteins were found to 
increase by at least two fold, which includes ATP-citrate synthase, ADP-ribosylation 
factor 1 (ARF1), and phosphatidylinositol 4-phosphate 3-kinase C2 domain 
containing subunit gamma.  Interestingly, ADP-ribosylation factors, including ARF1, 
have been shown to participate in membrane curvature and budding to form 
extracellular vesicles.91,92  Three proteins that participate in chemokine signaling that 
were identified include mitogen-activated protein kinase 3, cell division control 
protein 42 homolog and signal transducer and activator of transcription.  Additional 
proteins of interest that were found to increase in abundance due to heightened 
inflammatory conditions are the biosynthetic proteins serine-tRNA ligase 
cytoplasmic, valine-tRNA ligase, aminopeptidase B, fatty acid synthase, ATP-citrate 
synthase, and elongation factor 1-gamma.  Lastly, the vacuolar sorting-associated 
protein 35 was also found to increase in abundance, which is of interest because this 







Table 2: Proteins with significantly greater abundance in inflammatory exosomes 
(Rsc ≥1 and FDR ≤0.05). Rsc is reported as the log2 ratio of inflammatory versus 
conventional exosomes. 
Accession Protein RSC FDR 
Q5SS00 DBF4-type zinc finger-containing protein 2 
homolog 
3.6 1.48E-03 
Q8VDP4 DBIRD complex subunit KIAA1967 
homolog 
3.1 1.39E-02 
E9QQ35 Phosphatidylinositol 4-phosphate 3-kinase 
C2 domain-containing subunit gamma 
3.1 1.10E-03 
P12970 60S ribosomal protein L7a 3.0 2.29E-02 
P84078 ADP-ribosylation factor 1 3.0 2.29E-02 
P62908 40S ribosomal protein S3 2.8 4.49E-03 
P08730 Keratin, type I cytoskeletal 13 2.8 3.76E-02 
Q6ZQA0 Neurobeachin-like protein 2 2.8 3.76E-02 
P26638 Serine--tRNA ligase, cytoplasmic 2.4 3.10E-02 
P42227 Signal transducer and activator of 
transcription 3 
2.4 3.10E-02 
Q9D154 Leukocyte elastase inhibitor A 2.4 2.75E-05 
Q9Z1Q9 Valine--tRNA ligase 2.2 7.61E-05 
Q8VCT3 Aminopeptidase B 2.0 1.48E-03 
P84096 Rho-related GTP-binding protein RhoG 1.9 1.91E-03 
P42932 T-complex protein 1 subunit theta 1.8 3.28E-02 




Q99KE1 NAD-dependent malic enzyme, 
mitochondrial 
1.8 2.29E-02 
O55029 Coatomer subunit beta' 1.7 1.49E-02 
Q9EQH3 Vacuolar protein sorting-associated protein 
35 
1.7 9.63E-03 
Q9CWJ9 Bifunctional purine biosynthesis protein 
PURH 
1.6 1.48E-03 
P80315 T-complex protein 1 subunit delta 1.5 2.40E-02 
P19096 Fatty acid synthase 1.4 4.22E-03 
P28293 Cathepsin G 1.3 1.72E-04 
Q63844 Mitogen-activated protein kinase 3 1.2 3.10E-02 
P60766 Cell division control protein 42 homolog 1.2 1.49E-02 
Q8CCK0 Core histone macro-H2A.2 1.2 1.91E-03 
Q9Z1Q5 Chloride intracellular channel protein 1 1.2 1.01E-02 
Q9D8N0 Elongation factor 1-gamma 1.2 6.62E-03 
Q91V92 ATP-citrate synthase 1.1 2.40E-02 
P62827 GTP-binding nuclear protein Ran 1.0 1.15E-03 
 
 While the abundance of approximately 15% of the 412 proteins identified was 
found to differ by at least two-fold or more, two proteins of interest whose 
abundances were not found to differ due to heightened inflammation include proteins 
S100A8 and S100A9.  These proteins are secreted by MDSC and are believed to form 
a heterodimer and drive the accumulation of MDSC, thereby increasing the immune 




Proteins S100A8 and S100A9 have also been shown to contribute to polarization of 
tumoricidal macrophages to that of a tumor promoting phenotype.7   
Because proteins S100A8 and S100A9 play a significant role in MDSC 
function and have been shown to be secreted extracellularly by MDSC, Dr. Suzanne 
Ostrand-Rosenberg’s laboratory sought to determine if the extracellular S100A8 and 
S100A9 were actually active in the form of exosomes.  The activity of S100A8 and 
S100A9 in MDSC-derived exosomes was assayed for MDSC chemotaxis and 
polarization of macrophages.  The chemotaxis of MDSC by MDSC-derived 
exosomes was determined by measuring the number of MDSC migrating from the 
upper chamber of a transwell containing a semipermeable membrane to the lower 
chamber containing MDSC-derived exosomes (Figure 5).   The MDSC-derived 
exosomes co-cultured with MDSC (upper chamber) were chemotactic for MDSC, 
approximately greater than 90% as chemotactic as the MDSC conditioned medium.  
When antibodies to S100A8 and S100A9 were added to MDSC-derived exosomes, a 
decrease in MDSC chemotaxis was observed.  The decrease in chemotaxis due to the 
presence of the antibody for S100A8 is consistent with that for media alone.  
Together, the results indicate that MDSC-derived exosomes contain biologically 
active S100A8 and S100A9 that are chemotactic for MDSC.  When the chemotaxis 
due to the MDSC-derived exosomes is compared to that of the conditioned media, the 






Figure 5: Exosomes shed by MDSC contain S100A8 andS100A9 proteins that are 
chemotactic for MDSC.  MDSC were placed in the upper compartment of transwells 
and either tumor-conditioned medium or MDSC shed exosomes ± antibodies to 
S100A8 or S100A9 were placed in the lower compartment.  The number of MDSC 
migrating to the lower compartment was determined after 3 hours of incubation.  
Values are the average ± SD of 3 independent cell counts of duplicate samples. 
 
 In addition to chemotaxis of MDSC, S100A8 and S100A9 contribute to the 
polarization of macrophages towards a tumor-promoting phenotype.  This 
polarization is attributed to cross-talk between MDSC and tumoricidal (or M1) 
macrophages.  MDSC produce IL-10, which decreases macrophage production of IL-
12, resulting polarization of M1 macrophages towards a tumor promoting (or M2-
like) phenotype.7 Here, the production of IL-12 by macrophages co-cultured with 
7.5x105 conventional MDSC or MDSC-derived exosomes from 1x, 2x, and 5x 




Ostrand-Rosenberg.  The results of the IL-12 assay indicate that MDSC-derived 
exosome contribute to the polarization of macrophages towards an M2-like 
phenotype, and this polarization correlates positively with the concentration of 




Figure 6: Exosomes shed by MDSC polarize macrophages from a tumoricidal M1 
phenotype to a tumor-promoting M2 phenotype by inhibiting macrophage production 
of IL-12. Type 1 macrophages were co-cultured alone, or in the presence of intact 
MDSC or exosomes shed by MDSC.  IL-12 production by macrophages was 
measured by ELISA. 
Summary 
 Mass spectrometry-based proteomics has been used to analyze the protein 
content of exosomes produced by MDSC and how conditions in the tumor 




been identified in exosomes from both conventional and inflammatory MDSC, which 
is similar to the protein content of the source cells.  Highly abundant proteins were 
found to include histones, proteins that participate in metabolism, as well as the 
proinflammatory proteins S100 A8 and S100A9.  While the total number of vesicles 
was not statistically different due to heightened inflammation in the tumor 
microenvironment, approximately 15% of the proteins identified were differentially 
abundant by 2-fold or more.  Proteins that were found to increase in abundance 
include coatomer subunit beta and vacuolar protein sorting-associated protein 35, 
which are reported to participate in membrane budding and protein sorting, 
respectively. 
 Though highly abundant in the exosomes, the relative abundances of proteins 
S100A8 and S100A9 were not found to change by at least 2-fold due to heightened 
inflammation. However, biological assay results demonstrate that the exosomes 
contain biologically active S100A8 and S100A9 that accounts for approximately 90% 
of the activity that is observed in conditioned medium.  Collectively, the biological 
assays illustrate the immunosuppressive activity associated with the MDSC is also 
mediated by the exosomes they produce.  While MDSC are reported to inhibit 
successful immunotherapy in cancer patients,30  the ability of exosomes to contribute 
to immune suppression suggests that extracellular vesicles may also need to be 
considered as obstacles to successful treatment.      
 




Chapter 3: Ubiquitinated Proteins in Exosomes Exocytosed 




Exosomes are formed through the invagination of the plasma membrane to 
form early endosomes that mature into late endosomes, which are multivesicular 
bodies that contain intraluminal vesicles.44, 94 While the overall pathway of exosome 
formation has previously been reported, the mechanism(s) through which protein, 
lipid, and RNA are sorted into exosomes remains poorly understood.1, 95 Interestingly, 
exosomes from multiple parental cell types are found to be enriched, relative to their 
parental cells, in Alix [ALG-2 (apoptosis-linked gene 2)-interacting protein X] and 
Tsg101 (tumor suppressor protein 101) proteins, which are known to participate in 
the endosomal sorting complex required for transport (ESCRT).1  ESCRT protein 
complexes participate in the sorting proteins at the endosomal limiting membrane,52 
which requires recognition of ubiquitinated proteins.  The identification of ESCRT-
related proteins in exosomes1, 22,53 and the overlapping pathways that participate in 
endosome formation between the ESCRT-dependent recycling of cell surface 
receptors and exosome formation has led to the speculation that exosome formation 




of four proteins from ESCRT-0 and ESCRT-I protein complexes has been shown to 
alter exosome secretion.53 
 As mentioned earlier, the ESCRT pathway is dependent on the recognition of 
ubiquitinated proteins through ubiquitin interaction motifs.20 Ubiquitin is a protein of 
approximately 8.5 kDa and forms an isopeptide bond through its C-terminal Gly76 
and an ε-amino group of a lysine belonging to another ubiquitin moiety or a substrate 
protein. 23-25 Conjugation of a ubiquitin molecule requires the activity of E1 ubiquitin-
activating enzymes, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin ligases.94 
Ubiquitin itself contains seven lysine residues (K6, K11, K27, K29, K33, K48, and 
K63), through which ubiquitin can form chains of various length and linkage types 
including linear or branched chains.95-97 Recently, there have also been reports of 
ubiquitination at residues other than lysine, including serine, threonine and 
cysteine.98-100 
 Ubiquitination serves as a post-translational modification that alters protein 
interactions, subcellular localization and/or promotes protein degradation.96, 101,102 
The most well studied role of ubiquitination is the activity associated with K48-linked 
ubiquitin, which targets proteins to the 26S proteasome for subsequent 
deubiquitination and degradation.103-104 It has been reported that the most efficient 
signal for proteasomal degradation is K48-linked ubiquitin chains longer than four 
ubiquitin moieties.95 Also worth noting is that substitution of K48 to arginine causes 
cell death.105 Endocytosis of cell surface receptors and protein trafficking are 
associated with K63-linked polyubiquitin and monoubiquitination.95,106  Additional 




and DNA repair.108  Among polyubiquitin chains identified from yeast cells, K48- 
and K63-linked ubiquitin are the most abundant linkages identified.20,24,95 However, it 
is important to note that many ubiquitin conjugates are believed to be short-lived and 
therefore care must be taken during sample preparation.24 
Proteomic characterization of ubiquitinated proteins has been much slower 
than other post-translational modifications, including phosphorylation and 
methylation,109 which is in part due to the challenges associated with localizing the 
modification site in substrate proteins.  Recent progress has been made using His-
tagged ubiquitin conjugates110 and anti-ubiquitin antibodies.111 Following enrichment 
or purification of ubiquitinated proteins, the conjugates are typically digested with 
trypsin which cleaves C-terminally to Arg and Lys, including Arg74 of ubiquitin, 
which generates a ubiquitin remnant of Gly75 and Gly76 on the ubiquitinated lysine 
of a substrate protein.  The fragment ion mass spectrum of a tryptic peptide 
containing the glycinylglycine ubiquitin remnant will contain two fragment ions with 
a mass difference of 242.12 Da corresponding to a glycinylglycine-modified lysine.  
This modification can be identified using available bioinformatic tools by allowing 
for a variable modification of glycinylglycine of lysine.24 However, if a substrate 
protein contains one ubiquitination site, there would only be one lysine in the entire 
sequence carrying the modification.   
The stoichiometry of unmodified peptides to peptides containing a ubiquitin 
remnant is not favorable for mass spectrometry analysis.  This has led to the 
development of an antibody that recognizes glycinylgycine-modified lysine residues.  




antigen, which is lysine-rich, containing glycinylglycine-modified lysines.109 Peptide-
level enrichment of glycinylglycine-modified lysines, from whole cell extract, has 
been shown to greatly improve the identifications of tryptic peptides containing the 
ubiquitin remnant.98 In fact, over 10,000 glycinylglycine-modified lysines have been 
identified in over 4,000 proteins.112,113 
Our goal is to identify ubiquitinated proteins in MDSC-derived exosomes in 
order to provide insight into exosome formation and/or function.  It is important to 
note that most reports that demonstrate the identification of up to 4,000 ubiquitinated 
proteins start from milligram quantities of whole cell extract followed by peptide 
level enrichment for gylcinylglycine-modified lysines114 or His-tagged ubiquitin.24 In 
order to identify endogenous ubiquitinated proteins from limited starting material of 
MDSC-derived exosomes, an optimized immunoaffinity strategy was developed 
which included (1) protein level enrichment for ubiquitinated proteins followed by (2) 
peptide level enrichment for tryptic peptides containing gylcinylglycine-modified 
lysines.   
Materials and Methods 
 Myeloid-derived Suppressor Cells 
 BALB/c mice were injected in the mammary fat pad with approximately 7000 
4T1 mammary carcinoma cells stably transfected to express IL-1β.  When tumors 
were greater than approximately 8 mm in diameter (about 3-4 weeks after initial 
inoculation), MDSC were harvested from the blood, stained with fluorescently 
labeled monoclonal antibodies against markers of MDSC (Gr1 and CD11b), and 




Gr1+CD11b+ were used in all experiments.8 For each experiment, a total of about 1 x 
108 MDSC were pooled from 2 to 3 mice. The UMBC and UMCP Institutional 
Animal Care and Use Committees approved all procedures with animals and animal-
derived materials. 
 Exosomes 
 MDSC were plated in serum-free HL-1 medium (Bio-Whittaker, Walkersville, 
MD) and maintained at 37 °C with 5% CO2. After 18 hours, the cultures were 
centrifuged at 805 x g for 5 min (Eppendorf 5810 rotor, Eppendorf, Hamburg), the 
pellets were discarded, and the supernatants were centrifuged at 2090 x g for 30 
minutes (Sorvall RC5C, SS34 rotor, DuPont, Wilmington, DE). The supernatants 
were then ultracentrifuged at 100,000 x g for 20 hours at 10 °C (Beckman L8, 
SW40Ti rotor, Beckman, Pasadena, CA). The supernatants were discarded, and the 
pellets containing the exosomes were resuspended in PBS. Absorbances were 
measured at 260 and 280 nm. Exosomes were stored at -80 °C until use. 
 Exosomes were lysed in an optimized lysis buffer of 8 M urea in 50 mM 
ammonium bicarbonate with 50 µM of deubiquitinase inhibitor PR-619 (LifeSensors, 
Malvern, PA) and 1% of a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, 
MO).  The exosomes in lysis buffer were centrifuged at 14,000 x g for 30 minutes 
with a 3 kDa molecular weight cutoff filter, and the supernatants were discarded. The 
process was repeated three times with the retentate from the previous wash step.  
After lysis, the buffer was diluted to <0.8 M urea in 50 mM ammonium bicarbonate.  
Protein content before the immunoprecipitation was measured by the Quick Start 




 Immunoprecipitation of Ubiquitinated Proteins 
 Ubiquitinated proteins were enriched using Protein A-Sepharose 4B beads 
(Invitrogen, Carlsbad, CA) that had been incubated with anti-ubiquitin antibody 3933 
(Cell Signaling Technology, Danvers, MA) in a 1:600 dilution with rotation for 4 
hours at 4 °C.  Excess antibody was removed from the beads by washing with 0.8 M 
urea in 50 mM ammonium bicarbonate and centrifuging three times at 3,000 x g for 2 
minutes.  One-hundred micrograms of exosome lysate was added to the Sepharose 
bead slurry and incubated with rotation overnight at 4 °C.  The unbound fraction was 
collected via centrifugation at 500 x g for 5 min. The Sepharose bead slurry was 
washed with 50 mM ammonium bicarbonate and centrifuged at 1,000 x g for 5 
minutes to remove non-specifically bound proteins.  Bound proteins were eluted by 
incubating the Sepharose bead slurry in 0.2 M glycine, pH 2.6, for 1 hour at 4 °C and 
collected via centrifugation at 13,000 x g for 5 minutes.  The elution was repeated, 
and the two elution fractions were combined.115 Enriched fractions of ubiquitinated 
exosomal proteins were subsequently processed either by tryptic digestion in gel or in 
solution and immunoprecipitation of peptides containing glycinylglycine-modified 
lysine residues. 
 In-Gel Tryptic Digestion of Ubiquitinated Proteins 
 Proteomic studies were conducted on exosomal proteins enriched for ubiquitin 
conjugates by immunoprecipitation. Three biological replicates were resuspended in 
2% SDS, 5% β-mercaptoethanol, and 62.5 mM Tris HCl and reduced at 90 °C for 5 
minutes.  The samples were then loaded onto 8-16% polyacrylamide gels (Bio-Rad) 




50 W.  The gels were stained using Coomassie blue (40% methanol, 20% acetic acid, 
0.1% w/v Coomassie blue reagent 250; Thermo Scientific, San Jose, CA) stain and 
then excised into 13 slices.  After destaining, proteins were reduced in 10 mM 
dithiothreitol at 56 °C for 30 minutes and alkylated in the presence of 10 mM 
methylmethanethiosulfonate at room temperature for 45 minutes. Tryptic digestion 
was performed on each gel slice overnight at 37 °C.116 The extracted tryptic peptides 
were resuspended in 0.1% formic acid for injection into the LC-MS/MS. (See below 
for instrumental conditions) 
Tryptic Digestion and Immunoprecipitation of Glycinylglycine-Modified 
Peptides 
Enriched fractions of ubiquitinated exosomal proteins from five biological 
replicates were frozen, lyophilized and resuspended in 50 mM ammonium 
bicarbonate.  Proteins were reduced with 20 mM dithiothreitol for 30 minutes at 56 
°C and alkylated with 10 mM methylmethanethiosulfonate for 45 minutes.  One 
microgram of trypsin was added to each fraction, and digestion was performed 
overnight at 37 °C.  As a positive control, a ubiquitin dimer linked with an isopeptide 
bond at K48 (LifeSensors, Malvern, PA) was also digested with trypsin under these 
conditions. 
Peptides with glycinylglycine-modified lysine residues were enriched using 
Protein A-Sepharose 4B beads coupled to anti-diglycyl-lysine antibody GX41 
(Millipore, Billerica, MA) using the same procedure as that with the anti-ubiquitin 
antibody, except that anti-diglycyl-lysine antibody was prepared at a 1:1000 dilution.  




Sepharose bead slurry and incubated with rotation overnight at 4 °C.  The unbound 
fraction was removed via centrifugation at 500g for 5 minutes.  The Sepharose bead 
slurry was washed with 50 mM ammonium bicarbonate and centrifuged at 1,000g for 
10 seconds to remove non-specifically bound peptides.  Bound peptides were eluted 
by incubating the Sepharose bead slurry in 0.2 M glycine, pH 2.6, for 1 hr at 4 °C and 
collected via centrifugation at 13,000g for 5 minutes. The elution was repeated, and 
the two elution fractions were combined.  Prior to LC-MS/MS analysis, all fractions 
were desalted with C18 TopTip spin columns (Glygen, Columbia, MD) and 
resuspended in 0.1% formic acid. 
Western Blotting 
All fractions were subjected to one-dimensional gel electrophoresis on an 8-
16% Criterion precast gel (Bio-Rad) at 200 V, 50 mA, and 15 W for 56 minutes, 
followed by transfer to a PVDF membrane (EMD Millipore, Billerica, MA) at 100 V, 
350 mA, and 35 W for 1 hr.  Free ubiquitin, monoubiquitinated and polyubiquitinated 
proteins were detected by blotting with anti-ubiquitin antibody 3933 (Cell Signaling 
Technology) followed by anti-mouse IgG-HRP (Cell Signaling Technology).  Protein 
bands were visualized with an Image Lab System (Bio-Rad, Hercules, CA) using the 
Gel-Doc program (Kodak Molecular Imaging Systems) and the SuperSignal West 
Dura chemiluminescent substrate (Thermo Fisher Scientific, Waltham, MA). 
Extraction of Histones 
Exosomal histones were extracted using the EpiQuick Total Histone 




instructions and analyzed for ubiquitination via western blotting with anti-ubiquitin 
antibody 3933 as previously described. 
LC-MS/MS and Bioinformatic Analysis 
LC-MS/MS analyses were performed on a Shimadzu Prominence nano HPLC 
(Shimadzu Scientific Instruments, Columbia, MD) in-line with an LTQ-Orbitrap XL 
(Thermo Fisher Scientific). A 10 µL aliquot of tryptic peptides was injected onto an 
Acclaim PepMap 300 C18 pre-column (Dionex, Sunnyvale, CA) followed by 
desalting with 10% solvent A (97.5% H2O, 2.5% acetonitrile, and 0.1% formic acid) 
in 85 minutes, followed by an increase from 40 to 85% solvent B (97.5% acetonitrile, 
2.5% H2O, and 0.1% formic acid) in 85 minutes, followed by an increase from 40 to 
85% solvent B in 20 minutes. The flow rate was 500 nL/min.  Precursor scans were 
acquired in the orbitrap with a resolution of 30,000 at m/z 400. In each cycle, the nine 
most abundant ions were selected for fragmentation by collisional induced 
dissociation, and product ion scans were acquired in the LTQ. A dynamic exclusion 
of 1 repeat count over 180 seconds was used. 
Peptide and protein identifications were made by the PepArML76, 117 meta-
search engine against the UniProt mouse database (July 2014).  For the in-gel 
digestion, all peptide identifications were filtered at 10% spectral FDR, and proteins 
were required to be supported by at least 2 unshared peptides, bounding a protein 
FDR at 1%. For the two-step immunoaffinity enrichment of glycinylglycine-modified 
lysine-containing peptides, all peptides were filtered at 5% spectral FDR.  A fixed 
modification included methylthio of cysteine residues and variable modifications of 




Proteins with at least one peptide containing a glycinylglycine-modified lysine were 
considered to be ubiquitinated.  For all protein identifications based on a single 
peptide form the double immunoaffinity workflow, spectra are included in Appendix 
Figure 1.  Subcellular location and function assignments for all protein identifications 
were made using the Protein Information Resource GO Slim 
(http://pir.georgetown.edu) using UniProt Gene Ontology annotations (July 2014). 
Results and Discussion 
Western blotting was first used to determine if MDSC-derived exosomes do in 
fact contain ubiquitinated proteins using a general ubiquitin antibody that recognizes 
free ubiquitin as well as monoubiquitinated and polyubiquitinated proteins.  
Additionally, antibodies specific to K48- and K63-linked polyubiquitin were also 
used.  The Western blots shown in Figure 7 confirm the presence of ubiquitinated 
proteins in MDSC-derived exosomes as well as the presence of polyubiquitin chains 
containing K48- and K63-linkages.   
 
Figure 7: Western blots of lysates from MDSC-derived exosomes. Antibodies used 





 In order to identify the exosomal substrate proteins carrying the ubiquitin 
modification(s) an immunoaffinity enrichment strategy was optimized.  As noted 
earlier, most of the previous reports in which whole cell extracts were lysed and 
enriched at the peptide level for glycinylglycine-modified lysine-containing peptides 
started with milligram quantities of starting material; however, the amount of material 
that can be obtained from BALB/c mice carrying 4T1 mammary carcinoma is limited 
to approximately 100 µg per biological replicate.  Moreover, it has been reported that 
deubiquitinating enzymes may be present in biological samples, which would 
significantly underestimate the number of ubiquitinated proteins identified.  In order 
to address the second issue regarding deubiquitinating enzymes, exosome lysis and 
enrichment of ubiquitinated proteins was performed in the presence of a general 
deubiquitinatase (DUB) inhibitor PR-619.  The Western blot in Figure 8 
demonstrates the presence of DUB inhibitor PR-619 is required in order to maintain 
isopeptide linkage(s) between ubiquitin and substrate proteins due to the increase in 








Figure 8: Western blot of lysates from MDSC-derived exosomes in the (left) absence 
and (right) presence of DUB inhibitor PR-619. Antibodies used are anti-ubiquitin 
3933 and anti-K48-linked polyubiquitin. 
 
 Next, in-gel digestion of enriched ubiquitinated proteins, following 
immunoaffinity enrichment at the protein level using Sepharose beads coupled to 
anti-ubiquitin 3933 antibody, was evaluated by LC-MS/MS analysis.  Mass 
spectrometry-based proteomic analysis resulted in 16 protein identifications from 
three biological replicates (Table 3).  In order to report an exosomal protein as 
ubiquitinated, at least one tryptic peptide containing a gylcinylglycine-modified 
lysine must be observed. Initial peptide identifications and protein assignments were 
made by the PepArML meta search engine followed by manual curation of all tandem 
mass spectra assigned to confirm localization of the gycinylglycine-modified lysine.  
Results from the in-gel digestion of exosomal proteins enriched for ubiquitinated 
proteins suggested that unmodified tryptic peptides were suppressing the 
identification of tryptic peptides containing the ubiquitin remnant, glycinylglycine-




ubiquitinated.  In order to overcome this challenge, a second immunoaffinity 
enrichment was evaluated following the protein-level enrichment for ubiquitinated 
proteins and in-solution tryptic digestion.  LC-MS/MS analysis of tryptic peptides 
obtained from a second enrichment using anti-diglycyl lysine antibody GX41 coupled 
to Sepharose beads resulted in 38 protein identifications from five biological 
replicates (Table 4).  It is important to note that while the enrichment for 
glycinylglycine-modified lysine-containing peptides improved the identification of 
ubiquitinated exosomal proteins, the experimental design leads to several proteins 
based on single peptide identifications.   These peptides are less reliable than the 
peptides listed in Table 3, and annotated spectra for single peptide identifications 
have been included in Appendix Figure 1.   
 
Table 3: Ubiquitinated proteins and peptides identified from in-gel digestion of 
exosomal proteins with glycinylglycine-modified lysine residues. 
 
Protein  
















P61161 Actin-related protein 2  3 6.486E-04 
VVVCDNGTGFVK(G
G) 
P26040 Ezrin  3 6.490E-04 EELMLRLQDYEQK(GG)TKR 
P17156 Heat shock-related 70 kDa protein 2  5 4.860E-06 
HWPFRVVSEGGK(G
G)PK(GG) 
P63158 High mobility group protein B1 Ψ 4 5.614E-04 WK(GG)TMSAK(GG) 





































Q07133 Histone H1t  3 
6.486E-04 GKGK(GG)KSASAK(GG) 
  TK(GG)AVKKPKATPTK(GG) 
P27661 Histone H2A.x Ψ 5 4.860E-06 K(GG)SSATVGPK(GG)APAVGKK 
P62806 Histone H4 Ψ 6 4.207E-07 GKGGK(GG)GLGK(GG)GGAK 
Q6IFX2 Keratin, type I cytoskeletal 42 Ψ  9 2.729E-10 
NK(GG)ILAATIDNAS
IVLQIDNAR 
P08071 Lactotransferrin  29 1.522E-31 GDADAMSLDGGYIYTAGK(GG) 
P52480 Pyruvate kinase isozymes M1 Ψ 7 3.640E-08 
GPEIRTGLIKGSGTA
EVELK(GG)K 









Table 4: Ubiquitinated proteins and peptides identified following immunoaffinity 
enrichment of tryptic peptides with glycinylglycine-modified lysine residues. 
Protein 





















































P08113 Endoplasmin 2 1 3.63E-02 LLKVIRK(GG)KLVR 




















P43274 Histone H1.4* Ψ 4 2 
8.66E-02 AKKPAGAAK(GG) 
8.66E-02 TVKPKAAKPK(GG)TSK(GG) 



























Keratin, type I 
cytoskeletal 42* 
Ψ 









1 1 8.52E-03 MKGIQMLWADGKK(GG)AR 
Q0P5X1 
Leucine-rich 
repeat and IQ 
domain-
containing       
protein 1 





P51960 Myb-related protein A 1 1 8.52E-03 
WSLIAK(GG)H
LK(GG)GR 




















H3BL88 Protein 9930021J03Rik 2 1 5.10E-02 
K(GG)LKLTKM
RAKKKKKKK 




J3QQ16 Protein Col6a3 1 1 3.63E-02 DLK(GG)IMVLMLTGDMQR 
A2AU83 Protein GM14124 1 1 1.02E-02 
AFSSPSGFLYH
K(GG)R 




































linker 1 Ψ 



















e repeat protein 
14 















TFIID subunit 3 










enzyme E2 O Ψ 




* Indicates that the protein was also identified in the in-gel digestion. 
Ψ Indicates that the protein is reported previously to be ubiquitinated. 
 
Together, a combined total of 65 tryptic peptides were identified containing 
gylcinylglycine-modified lysines corresponding to 50 ubiquitinated proteins 
(Appendix Table 3).  From the combined cohort of 50 proteins, only ten of the 
proteins were previously identified in a proteomic survey of MDSC-derived 
exosomes, which highlights that enrichment of ubiquitinated proteins enables the 
identification of low abundance proteins that may not be identified in a complex 
sample.  Consistent with the Western blots in Figures 7 and 8, polyubiquitin peptides 
containing glycinylglycine-modifications at K6 and K63 were identified following 
enrichment for glycinylglycine-containing peptides (Table 4).  The identification of 
peptides assigned to polyubiquitin serves as an additional confirmation that the 
enrichment of ubiquitinated proteins was successful.  The experimentally observed 
glycinylglycine-modified lysine residues were compared to ubiquitination sites 
predicted in silico by a ubiquitination prediction tool, UbiProber.118 Of the 65 
ubiquitin remnant-containing peptides identified, the modification site of 42 peptides 
were also predicted with probabilities > 0.7, meeting UbiProber’s confidence level. 
Histones were identified as ubiquitinated with multiple conjugation sites and 
multiple unique peptides in both the in-gel digestion and two-step immunoaffinity 
enrichment of ubiquitinated exosomal proteins.  Another protein of interest identified 
as ubiquitinated in exosomes includes high mobility group protein B1 (HMG B1). 




tumor microenvironment and contributes to the differentiation of MDSC and their 
associated immune suppressive activity.119 However, the effect of ubiquitin on 
HMGB1 is not yet known. 
From the combined list of 65 ubiquitin remnant-containing peptides, 15 
peptides correspond to tryptic cleavage at glycinylglycine-modified lysine residues.  
This aberrant tryptic cleavage has been previously observed by others.25,109 Tryptic 
digestion of K48-linked ubiquitin dimer was performed to confirm the identification 
of aberrant tryptic cleavage.  In addition to the expected peptide containing a missed 
cleavage at the glycinylglycine-modified lysine (LIFAGKGGQLEDGR), the aberrant 
peptide corresponding to enzymating cleavage of the glycinylglycine-modified lysine 
(LIFAGKGG) was also identified by tandem mass spectrometry (Figure 9).  The ratio 
of the expected glycinylglycinyl-product to the novel peptide is approximately 5:1, 
estimated by peak areas in selected ion chromatograms. 
 
Figure 9: Tandem mass spectrum of the aberrant tryptic peptide (LIFAGKGG) 





Following identification of ubiquitinated exosomal proteins, the ubiquitinated 
cohort of 50 ubiquitinated proteins was compared to 412 proteins identified from a 
proteomic survey of MDSC exosome lysate16 to determine if the ubiquitinated cohort 
exhibits unique characteristics.  Figure 10 presents a comparison of the UniProt 
subcellular localizations of exosomal proteins (referenced to the location in the 
parental cell), which demonstrates that the ubiquitinated cohort contains an increased 
percentage of nuclear proteins and a significantly lower percentage of cytosolic and 
plasma membrane proteins.  The nuclear proteins identified in the ubiquitinated 
cohort include nine histones as well as other nucleic acid binding proteins 
(transcription factor A; density regulated protein; transcription initiation factor TFIID 
subunit 3, and protein Bodl1) (Tables 3 and 4).  It is important to note that histones, 
especially linker histones such as the histone H1 family, have been reported to be 
located in the cytoplasm and cell surface in addition to the nucleus120 and several 
histones have been previously reported to be ubiquitinated.121-123 The observation of 
ubiquitinated histones in MDSC-derived exosomes was confirmed by Western blot 
using anti-ubiquitin 3933 antibody following histone isolation from a total histone 
extract kit.  Interestingly, 12 of the ubiquitinated proteins identified in MDSC-derived 
exosomes have no assigned cellular location.  This is consistent with a previous report 
of the ubiquitinated proteins present in yeast expressing His-tagged ubiquitin,24 where 
most of the proteins identified did not have assigned subcellular locations present in 





Figure 10: Protein locations assigned to MDSC-derived exosomal lysate (412 
proteins) in grey and the ubiquitinated cohort (501 proteins) in black. Some proteins 
have multiple locations.  
  
Next, gene ontology annotations and the UniProt database were used to 
compare the distribution of protein sizes (sans ubiquitin), grand average of 
hydropathicity (GRAVY) scores, and isoelectric points of the ubiquitinated cohort to 
the 412 proteins identified in proteomic survey of MDSC exosomes.  The intact 
masses of the proteins identified in the ubiquitinated cohort are evenly distributed 
between 11 and 327 kDa (sans ubiquitin).  The GRAVY score and pI distributions of 
the ubiquitinated cohort are shown in Figure 11.  Although both the ubiquitinated 
cohort and proteomic survey of MDSC exosomes illustrate a wide range of GRAVY 




cluster as hydrophilic and basic proteins.  Seventy-two percent of the proteins 
identified in the ubiquitinated cohort have a GRAVY score less than -0.5, and 50% of 
the ubiquitinated proteins have pI values greater than 9.00.  Ubiquitin was not 
included in the calculation of GRAVY scores and pI values; however, monomeric 
ubiquitin has a GRAVY score of -0.489 and a pI value of 6.56.  The observed bias of 
ubiquitinated proteins towards a high pH is consistent with observations reported by 
Chen and coworkers,118 who reports that ubiquitinated proteins contain a greater 
abundance of positively charged amino acids. 
Interestingly, 34 of identified proteins in the ubiquitinated cohort have not 
previously been reported to be ubiquitinated (Tables 3 and 4).  Among these, sorting 
nexin 13 has been observed to participate in endosomal trafficking of ubiquitinated 
proteins.124 Identification of two ubiquitinated keratins is consistent with the proposed 
role of protein aggregation in invagination, which is the initial step in exosome 
formation.62,125 Other ubiquitinated proteins that are thought to play important roles in 
endosome and exosome formation include leucine zipper EF hand-containing 
transmembrane protein 1 (LETM1) and endoplasmin. Although the functions of the 
ubiquitinated proteins are not known, these two unconjugated proteins participate in 
transporting and maintaining high luminal concentrations of Ca2+ required for 






Figure 11: Distribution of (top) grand average of hydropathicity score (GRAVY) and 
(bottom) isoelectric point of MDSC-derived exosomal lysate (412 proteins) in grey 





 Due to the role of ubiquitination in protein localization and degradation, as 
well as its effects on protein-protein interactions,96,101,102 it was the aim of this study 
to determine if MDSC-derived exosomes contain ubiquitinated proteins and to 
identify the substrate proteins that carry the modification(s).  Here tandem mass 
spectrometry and immunoaffinity enrichment were used successfully to identify 65 
exosomal peptides that contain the glycinylglycine ubiquitin remnant, which 
corresponds to 50 exosomal proteins.  Thirty-four of the proteins identified have not 
previously been reported to be ubiquitinated. Moreover, both Western blots and 
peptides identified as ubiquitin indicate that MDSC-derived exosomes contain 
polyubiquitinated proteins.  
The cohort of 50 ubiquitinated proteins includes five proteins associated with 
exosome formation.  This includes the two proteins known to participate in ion uptake 
and transfer, LETM1 and endoplasmin. Compared to a proteomic survey of exosome 
protein content (412 proteins), the ubiquitinated cohort has a greater abundance of 
nuclear proteins that includes ubiquitinated histones.  Given the recent report44 of 
exosomes transferring function mRNA to recipient cells, the presence of histones in 






Chapter 4: Conclusions and Prospectus 
 Mass spectrometry-based proteomics has been used in this work to 
characterize exosomes produced by the immunosuppressive cells, MDSC.  MDSC 
promote tumor progression through suppression of T cell activation and polarization 
of macrophages towards a tumor-promoting phenotype.31-33 This activity inhibits 
successful immunotherapy in cancer patients.30  MDSC have also been shown to 
produce extracellular vesicles that meet the criteria of exosomes.  The main objective 
of this work was to analyze the protein cargo of MDSC-derived exosomes in order to 
learn how these vesicles may contribute to immune suppression in the tumor 
microenvironment. 
 MDSC-derived exosomes were found to contain proteins that are considered 
characteristic of exosomes including annexins, tetraspanins and heat shock proteins.  
The spectral count method has identified 63 proteins whose abundance was found to 
differ by at least 2-fold or more due to heightened inflammation in the tumor 
microenvironment.  Proteins that were found to decrease in abundance participate in 
the innate immune response (C4b-binding protein and complement C3) and 
chemotaxis (myeloid cysteine-rich protein and platelet factor 4).  Additionally, 
proteins that increased in abundance due to heightened inflammation include proteins 
that participate in chemokine signaling (mitogen-activated protein kinase 3, cell 
division control protein 42 homolog and signal transducer and activator of 
transcription 3). Collectively, the effect of heightened inflammation on proteins that 
participate in innate immune response, chemotaxis, and chemokine signaling suggests 




 Together, the proteomic analysis and biological assays indicate that MDSC-
derived exosomes contain proteins that are representative of the parent cell and are 
biologically active.  The exosomes have been shown to be chemotactic for MDSC 
and contribute to the polarization of macrophages towards a tumor promoting 
phenotype.   Therefore, the exosomes contribute to the immune suppressive activities 
associated with MDSC in the tumor microenvironment.  Given the role of MDSC in 
inhibiting successful immunotherapy, these results suggest that exosomes produced 
by MDSC should also be considered as potential obstacles in successful treatment. 
 In this work, mass spectrometry-based proteomics was also used with 
immunoaffinity enrichment to characterize ubiquitinated exosomal proteins.  Some 
previous reports have demonstrated successful enrichment at the peptide level by 
enriching in one step for the glycinylglycine ubiquitin remnant.  However, most 
reports use His-tagged ubiquitin and/or start from milligram quantities of total 
protein.24,114 The method optimized in this study for the identification of endogenous 
ubiquitinated exosomal proteins from limited quantities of starting material is based 
on enrichment at the protein level for ubiquitinated proteins, followed by a peptide-
level enrichment for the glycinylglycine ubiquitin remnant.  This technique has been 
used to identify 50 ubiquitinated proteins in MDSC-derived exosomes, of which 34 
have not previously been reported to be ubiquitinated. 
 Among the cohort of 50 ubiquitinated proteins are five proteins that are 
associated with exosome formation as well as ubiquitinated histones. Interestingly, 
histones located outside of the nucleus, such as the cytoplasm and plasma membrane, 




interest to the exosome community to determine the location of the histones in the 
MDSC-derived exosomes.   
 As mentioned earlier, ubiquitin may have different effects on the conjugated 
protein depending on the ubiquitin linkage present as well as the degree of 
ubiquitination.  While the identification of the exosomal substrate proteins carrying 
this modification has provided new insight on the role of this post-translational 
modification in exosome formation and/or function, the effect of this post-
translational modification on the biological activity of the exosomal proteins is not 
yet known.  However, more information can be gleaned from identifying the linkage-
types present on the exosomal proteins as well as the degree of ubiquitination.  For 
example, it would be of great importance to learn if the majority of ubiquitin 

















Appendix Table 1: Protein identifications and corresponding spectral count ratio (Rsc) 
























l Count Rsc 
A1BN54 12 19.6 
1.29E-







A2AF47 2 1.8 
5.40E-







A2AN08 0 0.0 
1.00E+






A2AQ07 7 25.7 
2.05E-







A6ZI44 11 34.0 
1.09E-







D3Z6Q9 2 7.8 
1.12E-







D3Z7R7 2 3.0 
9.34E-







E9PV24 7 10.1 
2.65E-







E9Q0F0 1 1.1 
1.15E-










E9Q0K6 11 26.4 
1.47E-






E9Q133 7 28.4 
1.60E-






E9Q604 8 11.4 
3.67E-







E9QQ35 1 2.1 
7.84E-






F6W687 5 43.8 
1.13E-







F6YXS3 1 11.6 
1.15E-






F8WGL3 3 20.7 
3.57E-








5 3 8.9 
3.57E-







F8WH69 5 17.3 
5.89E-







F8WI35 28 65.2 
1.06E-







G3UZJ4 1 13.9 
1.15E-






G5E8N7 7 29.3 
1.16E-






H3BKH6 7 45.1 
4.44E-







O08692 15 58.7 
7.65E-









O08756 3 22.2 
2.20E-







O08810 2 4.5 
2.80E-







O08992 3 20.7 
1.10E-







O09061 3 18.8 
1.52E-







O35286 2 3.5 
1.32E-






O35350 2 4.8 
1.32E-






O35598 2 4.1 
1.32E-







O35639 3 12.7 
1.52E-






O35643 5 11.2 
5.30E-







O35744 6 23.9 
5.28E-







O54890 2 5.5 
1.32E-







O55029 2 3.2 
1.32E-






O55222 0 0.0 
1.00E+






O70133 3 5.2 
6.09E-










O70138 3 9.2 
1.52E-







O70145 7 25.9 
2.65E-






O70165 3 16.2 
1.52E-







O88342 5 11.2 
8.08E-






O88593 1 13.2 
1.15E-






O88685 2 7.0 
1.32E-






O88844 3 9.4 
1.32E-






O89053 17 58.6 
3.03E-







P01027 19 55.9 
1.34E-







P01325 2 14.8 
1.32E-







P01794 2 23.6 
9.58E-







P01837 2 45.3 
1.32E-






P01872 10 29.1 
4.03E-







P01942 15 84.5 
2.88E-










P02088 15 79.6 
1.08E-







P02089 10 78.2 
4.90E-







P02301 29 65.4 
6.07E-







P04104 3 3.8 
7.98E-







P04919 11 24.5 
3.19E-







P06151 9 36.1 
2.07E-







P06745 9 23.5 
7.29E-






P06800 2 2.6 
7.37E-







P07356 6 32.2 
6.21E-






P07724 16 35.4 
9.31E-






P07742 0 0.0 
1.00E+






P07901 3 6.5 
1.32E-






P08030 5 38.3 
2.01E-





P08032 17 14.2 
1.00E-















P08226 5 24.8 
2.01E-






P08249 4 16.3 
1.75E-







P08607 3 10.0 
1.52E-







P08730 0 0.0 
1.00E+





P08905 3 31.1 
1.52E-







P09411 9 36.9 
1.18E-






P09528 4 28.0 
1.65E-







P0C0S6 11 56.3 
3.05E-






P10107 14 46.5 
8.48E-







P10126 10 36.4 
3.78E-






P10605 2 9.1 
1.32E-







P10854 24 74.6 
5.76E-







P11247 21 33.7 
4.29E-






P11276 63 39.5 
1.22E-










P11352 4 33.8 
7.64E-






P11499 4 8.7 
1.83E-







P11672 2 17.0 
1.32E-







P11835 13 23.2 
1.78E-






P11983 4 10.8 
1.75E-






P12815 1 14.1 
1.15E-






P12970 0 0.0 
1.00E+






P13020 2 3.3 
3.11E-







P14069 3 32.6 
1.52E-







P14131 3 21.9 
1.52E-







P14152 2 11.1 
4.43E-







P14206 3 20.0 
3.26E-







P14685 2 4.5 
4.43E-






P14824 2 5.1 
2.56E-










P14869 2 10.1 
3.50E-







P15864 17 37.3 
1.75E-






P16546 2 1.8 
1.53E-







P16858 14 63.4 
4.79E-






P17182 15 44.5 
1.09E-






P17225 2 8.3 
4.17E-







P17427 5 9.1 
4.38E-







P17742 6 52.4 
1.48E-







P17751 2 14.4 
4.62E-







P19096 4 2.8 
2.10E-






P20029 9 17.6 
1.07E-







P20152 4 12.2 
1.75E-







P21107 1 7.3 
1.15E-












P24270 6 15.2 
6.11E-







P25911 3 10.0 
6.39E-





P26039 36 27.0 
2.01E-







P26040 7 11.4 
1.32E-







P26041 10 18.5 
8.79E-







P26443 2 5.9 
3.11E-






P26516 1 8.7 
1.15E-






P26638 1 3.1 
1.15E-






P27005 5 74.2 
1.01E-






P27773 2 5.0 
1.32E-






P27870 1 2.0 
5.14E-






P28293 7 31.0 
1.85E-






P28352 1 6.0 
4.61E-






P28650 5 15.4 
4.72E-





P28798 2 4.8 
1.32E-










P29351 13 39.2 
6.13E-






P29391 5 32.8 
1.52E-






P29788 4 10.9 
4.11E-







P30681 8 27.6 
2.26E-







P31230 1 3.9 
8.66E-







P31725 20 79.6 
2.81E-






P34884 1 18.3 
4.61E-






P35441 19 23.2 
2.21E-







P35700 1 5.5 
1.15E-







P39054 5 9.5 
2.32E-






P39654 2 5.7 
2.62E-







P39655 2 5.4 
2.46E-






P40124 10 36.5 
8.53E-







P40142 15 31.1 
1.05E-









P40201 1 0.7 
7.84E-







P41245 16 32.5 
7.70E-







P42227 1 3.4 
1.15E-






P42932 2 5.3 
1.32E-






P43274 17 37.4 
1.32E-





P43275 7 22.1 
1.75E-






P43276 10 26.5 
6.18E-







P45376 1 4.4 
1.15E-






P47738 13 43.9 
1.04E-






P47753 5 28.0 
4.62E-







P47754 4 21.3 
1.52E-







P47757 4 22.9 
1.75E-







P47791 3 10.1 
1.52E-







P47911 2 10.8 
1.32E-














P47962 2 8.1 
1.59E-







P48025 2 5.4 
8.22E-







P49722 4 23.5 
1.75E-







P50247 3 10.0 
4.46E-






P50516 2 8.1 
3.11E-






P50543 2 27.6 
1.86E-





P51150 1 6.3 
1.15E-






P51174 1 2.6 
1.15E-







P51437 3 35.8 
8.39E-







P52480 32 56.9 
2.95E-







P54071 2 4.9 
1.15E-






P54775 2 15.8 
3.11E-







P56480 1 3.6 
1.15E-






P57780 8 11.5 
1.32E-









P58252 12 25.4 
4.53E-






P59999 2 13.1 
1.32E-






P60122 2 6.6 
1.32E-






P60229 0 0.0 
1.00E+






P60335 3 12.1 
1.52E-






P60710 54 90.1 
6.93E-






P60766 1 8.9 
1.15E-






P60843 5 19.5 
1.65E-






P61161 8 31.2 
5.01E-






P61164 4 19.4 
1.75E-







P61979 2 10.9 
1.03E-






P62137 4 21.8 
1.74E-







P62196 2 8.6 
3.50E-







P62242 3 18.8 
5.04E-







P62259 3 20.8 
1.19E-










P62281 2 17.7 
4.62E-






P62315 2 27.7 
1.32E-







P62317 2 16.1 
5.32E-






P62320 3 31.7 
3.57E-







P62334 1 3.9 
6.58E-






P62702 2 4.6 
1.32E-






P62806 38 65.0 
5.56E-







P62814 2 6.7 
1.32E-






P62827 9 40.7 
3.93E-






P62855 2 23.5 
9.18E-







P62880 2 9.1 
1.59E-






P62889 2 30.4 
3.11E-






P62908 1 5.3 
2.70E-






P62962 5 37.1 
1.92E-







P63005 0 0.0 
1.00E+










45 E-51 71108 
P63085 2 6.7 
3.23E-






P63101 5 26.5 
1.12E-







P63158 3 14.9 
1.99E-






P63330 4 24.3 
1.75E-





P68033 34 67.9 
4.97E-






P68040 6 34.4 
6.78E-







P68254 2 21.8 
9.12E-







P68368 11 34.2 
4.11E-






P68372 11 40.9 
1.32E-







P68373 12 36.3 
2.01E-







P68433 27 65.4 
1.32E-






P68510 2 17.9 
1.32E-







P70168 7 15.5 
1.53E-







P70335 0 0.0 
1.00E+









P70390 40 13.8 
3.17E-







P70460 3 10.1 
1.83E-






P80313 2 7.5 
1.32E-






P80314 2 7.1 
1.32E-







P80315 4 13.2 
1.75E-






P80316 4 16.5 
2.53E-






P80317 2 7.0 
1.32E-






P82198 6 17.6 
4.06E-







P84078 0 0.0 
1.00E+






P84091 1 6.4 
1.15E-






P84096 5 30.9 
5.93E-






P84228 33 65.4 
1.52E-







P97369 5 23.6 
2.01E-






P97384 6 17.5 
5.43E-







P99024 12 44.8 
1.52E-










Q00519 7 10.4 
2.49E-







Q00612 17 44.3 
7.49E-






Q01853 20 38.3 
3.12E-







Q02053 17 26.8 
4.93E-






Q02357 5 62.8 
2.00E-







Q04750 4 9.3 
1.38E-







Q05144 6 39.1 
1.60E-






Q07076 2 5.4 
1.32E-






Q07797 2 6.8 
3.50E-






Q3TCJ1 0 0.0 
1.00E+






Q3TEA8 2 4.7 
1.32E-







Q3THE2 1 5.8 
1.15E-






Q3TRM8 11 18.0 
1.89E-





Q3TXS7 2 3.8 
1.94E-










Q3UGX2 5 3.5 
8.95E-








2 4 42.1 
2.29E-







Q3UP87 4 20.8 
1.75E-






Q3UW53 3 6.3 
1.79E-







Q3UZZ4 5 12.7 
2.01E-







Q3V1G4 1 2.5 
8.34E-






Q571I9 4 9.0 
1.75E-






Q5SQX6 3 1.7 
1.01E-







Q5SS00 0 0.0 
1.00E+






Q5SXR6 26 25.0 
3.53E-






Q60605 5 45.7 
1.32E-







Q60692 2 10.9 
1.32E-







Q61081 1 5.5 
1.15E-






Q61096 1 5.1 
1.15E-













Q61210 4 9.0 
1.08E-






Q61233 16 35.9 
1.16E-







Q61316 1 1.7 
1.38E-







Q61508 2 6.5 
2.95E-







Q61598 2 7.3 
1.32E-






Q61599 2 23.5 
1.32E-







Q61646 7 33.1 
4.24E-






Q61656 2 4.4 
1.32E-







Q61753 0 0.0 
1.00E+






Q61990 2 8.3 
1.32E-







Q62465 3 6.9 
6.39E-







Q63844 6 23.4 
2.01E-






Q64514 2 4.1 
2.96E-










Q64522 40 60.8 
2.65E-





Q64727 5 9.3 
9.16E-







Q69ZK0 1 5.0 
4.69E-







Q6GSS7 38 70.8 
1.32E-





Q6IRU2 2 10.9 
1.25E-







Q6P069 2 16.4 
1.32E-






Q6P4T2 2 2.1 
1.32E-







Q6P5F9 3 4.9 
1.83E-






Q6P9Q4 1 0.9 
9.05E-






Q6PDI5 2 2.1 
9.41E-







Q6PDQ2 1 0.9 
1.15E-






Q6PHN9 1 5.5 
1.15E-







Q6ZQ38 2 4.5 
1.59E-






Q6ZQA0 0 0.0 
1.00E+





Q6ZWR6 6 8.9 
4.51E-










Q76MZ3 5 16.6 
4.93E-






Q78PY7 2 4.0 
1.32E-







Q80TE4 0 0.0 
1.00E+






Q80X41 2 11.4 
1.86E-







Q8BFY9 0 0.0 
1.00E+






Q8BFZ3 20 43.4 
1.05E-






Q8BG32 3 8.5 
1.52E-






Q8BJY1 0 0.0 
1.00E+






Q8BT60 3 9.0 
1.52E-







Q8BTM8 34 242.6 
4.86E-







Q8BVQ9 3 12.0 
1.52E-







Q8BWT1 1 2.5 
1.15E-






Q8C147 4 10.8 
1.96E-






Q8C2Q7 3 10.6 
1.52E-







Q8CC86 0 0.0 
1.00E+









Q8CCK0 4 12.4 
1.38E-






Q8CG29 3 4.4 
1.52E-





Q8CGP1 24 74.6 
1.75E-







Q8CGP4 21 56.6 
1.52E-






Q8CIE6 4 3.9 
1.75E-






Q8CIH5 6 8.8 
3.34E-






Q8CIZ8 9 36.6 
1.41E-







Q8JZQ9 1 3.0 
3.04E-







Q8K0E8 12 36.4 
4.20E-







Q8K1B8 14 33.4 
2.15E-





Q8K1X4 2 4.0 
5.32E-







Q8K426 2 23.1 
1.32E-







Q8K482 4 5.8 
8.86E-







Q8QZY1 3 9.4 
1.52E-









Q8R010 2 12.8 
4.43E-






Q8R081 1 4.9 
1.15E-







Q8R1B4 3 2.9 
2.52E-






Q8R1Q8 2 5.9 
1.32E-







Q8R2S8 10 18.4 
4.85E-







Q8VCI0 0 0.0 
1.00E+







7 10 34.9 
9.48E-







Q8VCT3 4 11.7 
3.91E-





Q8VDD5 44 29.8 
5.27E-








4 3 6.2 
1.52E-







Q8VDP4 0 0.0 
1.00E+






0 2 11.0 
1.32E-







Q8VEK3 2 4.6 
1.32E-







Q8VHP7 2 11.3 
3.24E-










Q8VIJ6 2 7.9 
3.50E-







Q91V92 3 4.6 
1.52E-






Q91VI7 2 7.5 
2.29E-






Q91YP3 1 3.8 
1.15E-






Q91Z50 1 5.3 
1.15E-







Q921G6 0 0.0 
1.00E+






Q921I1 8 17.5 
7.17E-







Q921M3 3 5.8 
1.83E-







Q922B2 2 6.0 
1.59E-






Q922D8 1 1.6 
1.15E-






Q922U2 2 3.8 
6.49E-






Q93092 2 7.7 
5.28E-






Q99J77 1 8.9 
5.03E-






Q99JI4 1 4.4 
1.15E-






Q99JI6 2 12.5 
1.32E-










Q99JY9 12 50.0 
1.14E-






Q99K48 3 25.1 
3.57E-







Q99KE1 3 12.4 
1.25E-






Q99KI0 0 0.0 
1.00E+






Q99KK2 2 14.5 
9.58E-







Q99KP6 2 8.1 
4.62E-






Q99LB4 0 0.0 
1.00E+






Q99LC5 0 0.0 
1.00E+






Q99MK8 2 5.7 
5.34E-






Q99NB9 2 2.8 
2.74E-







Q99PV0 4 3.6 
7.84E-







Q9CQV8 5 32.8 
1.35E-







Q9CVB6 3 17.7 
8.96E-






Q9CW03 2 2.5 
1.07E-







Q9CWJ9 3 11.0 
6.21E-









Q9CZN7 1 7.5 
4.59E-






Q9CZU6 3 18.3 
2.13E-







Q9D0I9 1 2.4 
1.15E-






Q9D154 3 16.1 
1.52E-






Q9D2V7 7 19.8 
3.99E-






Q9D8N0 5 18.5 
2.01E-






Q9D906 1 4.3 
1.15E-






Q9DBG3 5 9.0 
1.59E-







Q9DBJ1 5 32.7 
5.31E-







Q9DCD0 8 23.8 
7.17E-






Q9DCH4 2 10.0 
1.32E-






Q9EPU0 0 0.0 
1.00E+






Q9EQH3 5 12.8 
6.03E-






Q9EQK5 12 25.2 
2.65E-






Q9ERK4 3 5.7 
2.49E-









Q9ESX5 1 3.9 
2.70E-







Q9ET01 25 38.6 
2.02E-






Q9JHK5 2 8.0 
1.32E-







Q9JHU4 13 5.5 
1.73E-







Q9JIF0 1 3.5 
1.15E-






Q9JIF7 2 4.2 
3.11E-






Q9JJ28 3 5.4 
4.02E-






Q9JKF1 21 20.5 
4.14E-







Q9JKR6 2 4.0 
3.11E-







Q9JL26 2 3.0 
1.32E-







Q9JM76 5 34.3 
3.01E-







Q9QUI0 3 24.9 
2.59E-







0 7 12.6 
7.51E-








9 4 17.9 
1.75E-









4 2 6.5 
1.04E-







Q9QXK3 4 9.3 
1.18E-







Q9QZD9 2 5.5 
1.32E-







Q9QZQ8 20 38.5 
1.92E-






Q9R062 4 24.6 
1.03E-






Q9R0N0 2 12.0 
1.59E-






Q9R0P5 3 26.1 
8.48E-






Q9R111 5 20.9 
8.50E-






Q9R1P0 3 21.5 
2.63E-







Q9R1P3 3 21.4 
1.52E-







Q9R1P4 2 8.7 
1.32E-







Q9WU78 10 22.2 
8.19E-








2 1 2.2 
9.94E-







3 2 10.7 
2.01E-










Q9WV32 8 31.7 
3.05E-







Q9WVJ2 3 12.2 
2.09E-








4 7 26.6 
1.63E-







Q9Z0N1 0 0.0 
1.00E+






Q9Z0P5 1 4.9 
4.69E-






Q9Z126 4 46.7 
1.75E-







Q9Z183 4 11.7 
5.07E-







Q9Z1E4 3 9.5 
1.52E-






Q9Z1Q5 5 39.0 
1.30E-






Q9Z1Q9 4 7.1 
1.19E-






Q9Z2L7 1 7.0 
1.38E-






Q9Z2U0 5 30.6 
5.31E-







Q9Z2U1 2 15.8 
1.32E-





















A1BN54 15 24.6 
6.43E-
24 Alpha actinin 1a 
A2AF47 2 1.8 
5.40E-
06 Dedicator of cytokinesis protein 11 
A2AN0
8 2 0.7 
9.00E-
06 E3 ubiquitin-protein ligase UBR4 
A2AQ0
7 9 32.4 
2.82E-
20 Tubulin beta-1 chain 
A6ZI44 12 39.2 
1.14E-
39 Fructose-bisphosphate aldolase 
D3Z6Q9 3 12.5 
1.77E-
08 Bridging integrator 2 
D3Z7R7 2 3.0 
3.26E-
06 
Minor histocompatibility protein 
HA-1 
E9PV24 7 10.1 
1.37E-
23 Protein Fga 
E9Q0F0 2 1.3 
7.94E-
07 Protein Krt78 





E9Q133 9 32.9 
1.08E-
29 
T-complex protein 1 subunit 
gamma 
E9Q604 8 11.4 
3.96E-
25 Integrin alpha-M 




3-kinase C2 domain-containing 
subunit gamma 
F6W687 5 43.8 
6.12E-
15 
Non-histone chromosomal protein 
HMG-17 (Fragment) 










5 3 8.9 
3.68E-
10 
Syntaxin-binding protein 2 
(Fragment) 
F8WH6
9 9 28.2 
2.27E-
28 Neutrophil cytosol factor 1 
F8WI35 29 65.2 
6.02E-
12 Histone H3 











6 7 45.1 
1.12E-
22 S-formylglutathione hydrolase 
O08692 17 68.9 
4.41E-
51 Myeloid bactenecin (F1) 





O08810 2 4.5 
3.40E-
07 
116 kDa U5 small nuclear 
ribonucleoprotein component 
O08992 3 20.7 
3.84E-
09 Syntenin-1 
O09061 3 18.8 
1.85E-
10 Proteasome subunit beta type-1 
O35286 4 5.9 
2.13E-
13 
Putative pre-mRNA-splicing factor 
ATP-dependent RNA helicase 
DHX15 
O35350 5 11.5 
1.84E-
16 Calpain-1 catalytic subunit 
O35598 2 4.1 
4.61E-
07 
Disintegrin and metalloproteinase 
domain-containing protein 10 
O35639 4 17.3 
2.13E-
13 Annexin A3 
O35643 5 11.2 
5.30E-
06 AP-1 complex subunit beta-1 
O35744 7 26.1 
1.12E-
21 Chitinase-3-like protein 3 
O54890 2 5.5 
1.32E-
06 Integrin beta-3 
O55029 3 5.7 
6.45E-
11 Coatomer subunit beta' 
O55222 2 7.7 
2.04E-
06 Integrin-linked protein kinase 
O70133 4 5.9 
3.31E-
13 ATP-dependent RNA helicase A 
O70138 3 9.2 
1.85E-
10 Neutrophil collagenase 
O70145 10 32.2 
7.99E-
33 Neutrophil cytosol factor 2 
O70165 3 16.2 
1.52E-
09 Ficolin-1 
O88342 8 22.3 
2.72E-
25 WD repeat-containing protein 1 





O88685 3 9.3 
6.45E-
11 26S protease regulatory subunit 6A 
O88844 5 13.3 
5.15E-
14 
Isocitrate dehydrogenase [NADP] 
cytoplasmic 
O89053 20 60.7 
1.74E-
62 Coronin-1A 
P01027 19 55.9 
1.03E-
59 Complement C3 
P01325 2 14.8 
1.61E-
07 Insulin-1 
P01794 2 23.6 
9.58E-
06 Ig heavy chain V region HPCG14 
P01837 2 45.3 
1.32E-
06 Ig kappa chain C region 
P01872 10 29.1 
6.94E-
32 Ig mu chain C region secreted form 
P01942 15 84.5 
2.99E-
47 Hemoglobin subunit alpha 
P02088 15 79.6 
1.11E-
28 Hemoglobin subunit beta-1 
P02089 10 78.2 
1.71E-
12 Hemoglobin subunit beta-2 
P02301 29 65.4 
1.62E-
09 Histone H3.3C 
P04104 3 3.8 
4.35E-
10 Keratin, type II cytoskeletal 1 
P04919 11 24.5 
3.19E-
32 Band 3 anion transport protein 
P06151 10 38.6 
3.27E-
32 L-lactate dehydrogenase A chain 
P06745 12 28.3 
1.26E-
39 Glucose-6-phosphate isomerase 





P07356 7 34.8 
6.38E-
23 Annexin A2 
P07724 16 35.4 
2.74E-
49 Serum albumin 




reductase large subunit 
P07901 5 9.4 
6.45E-
11 Heat shock protein HSP 90-alpha 
P08030 5 38.3 
1.04E-




P08032 17 14.2 
1.00E-
47 Spectrin alpha chain, erythrocytic 1 
P08071 54 72.0 
3.78E-
175 Lactotransferrin 
P08226 5 24.8 
2.01E-
15 Apolipoprotein E 





P08607 3 10.0 
1.52E-
09 C4b-binding protein 
P08730 2 6.8 
6.30E-
07 Keratin, type I cytoskeletal 13 
P08905 3 31.1 
1.85E-
10 Lysozyme C-2 
P09411 12 47.0 
2.01E-
40 Phosphoglycerate kinase 1 
P09528 4 28.0 
1.39E-
12 Ferritin heavy chain 
P0C0S6 14 56.3 
6.15E-
34 Histone H2A.Z 
P10107 15 46.5 
2.58E-
49 Annexin A1 
P10126 13 40.7 
1.51E-
39 Elongation factor 1-alpha 1 
P10605 2 9.1 
1.32E-
06 Cathepsin B 
P10854 25 74.6 
1.48E-
12 Histone H2B type 1-M 
P11247 28 40.4 
3.59E-
93 Myeloperoxidase 
P11276 66 40.7 
3.81E-
200 Fibronectin 
P11352 5 39.3 
5.73E-
16 Glutathione peroxidase 1 
P11499 5 10.2 
2.23E-
10 Heat shock protein HSP 90-beta 





P11835 14 25.7 
3.32E-
41 Integrin beta-2 
P11983 8 20.3 
2.64E-
26 T-complex protein 1 subunit alpha 
P12815 3 35.1 
1.41E-
08 Programmed cell death protein 6 





P13020 3 4.8 
1.25E-
09 Gelsolin 
P14069 3 32.6 
6.45E-
11 Protein S100-A6 
P14131 3 21.9 
5.30E-
10 40S ribosomal protein S16 





P14206 4 25.4 
3.47E-
12 40S ribosomal protein SA 
P14685 4 14.3 
6.03E-
12 
26S proteasome non-ATPase 
regulatory subunit 3 
P14824 3 6.4 
1.03E-
08 Annexin A6 
P14869 3 20.5 
1.38E-
09 60S acidic ribosomal protein P0 
P15864 23 37.7 
3.25E-
23 Histone H1.2 
P16546 3 2.7 
1.07E-
07 
Spectrin alpha chain, non-
erythrocytic 1 





P17182 20 50.7 
1.64E-
64 Alpha-enolase 





P17427 6 11.2 
8.15E-
19 AP-2 complex subunit alpha-2 
P17742 6 52.4 
3.42E-
20 
Peptidyl-prolyl cis-trans isomerase 
A 
P17751 4 25.4 
8.12E-
12 Triosephosphate isomerase 
P19096 12 8.9 
2.52E-
39 Fatty acid synthase 
P20029 10 19.2 
3.75E-
21 78 kDa glucose-regulated protein 
P20152 4 12.2 
6.09E-
13 Vimentin 
P21107 2 12.5 
6.19E-
07 Tropomyosin alpha-3 chain 
P22752 50 70.8 
9.03E-
62 Histone H2A type 1 






P25911 5 14.7 
1.04E-
17 Tyrosine-protein kinase Lyn 
P26039 43 30.9 
1.02E-
131 Talin-1 
P26040 8 11.4 
5.30E-
10 Ezrin 
P26041 12 20.1 
3.42E-
22 Moesin 
P26443 3 8.8 
1.89E-
09 
Glutamate dehydrogenase 1, 
mitochondrial 
P26516 2 14.0 
4.61E-
07 
26S proteasome non-ATPase 
regulatory subunit 7 
P26638 3 11.5 
2.07E-
10 Serine--tRNA ligase, cytoplasmic 
P27005 7 92.1 
1.97E-
22 Protein S100-A8 
P27773 3 6.9 
3.68E-
10 Protein disulfide-isomerase A3 
P27870 2 3.7 
2.06E-
06 Proto-oncogene vav 
P28293 13 50.2 
3.48E-
42 Cathepsin G 
P28352 2 6.3 
3.27E-
05 
DNA-(apurinic or apyrimidinic 
site) lyase 





P28798 5 12.6 
1.72E-
15 Granulins 




receptor type 6 
P29391 6 48.6 
7.11E-
19 Ferritin light chain 1 
P29788 4 10.9 
4.11E-
12 Vitronectin 
P30681 10 38.1 
3.68E-
24 High mobility group protein B2 
P31230 2 9.4 
4.03E-
06 
Aminoacyl tRNA synthase 
complex-interacting 
multifunctional protein 1 
P31725 23 79.6 
1.40E-
73 Protein S100-A9 
P34884 2 26.1 
5.16E-
07 
Macrophage migration inhibitory 
factor 






P35700 2 16.6 
8.46E-
06 Peroxiredoxin-1 
P39054 9 16.4 
4.13E-
27 Dynamin-2 















P40142 20 40.0 
8.69E-
63 Transketolase 




binding protein 1 
P41245 16 32.5 
1.48E-
48 Matrix metalloproteinase-9 
P42227 3 10.4 
8.64E-
10 
Signal transducer and activator of 
transcription 3 
P42932 6 14.6 
2.81E-
20 T-complex protein 1 subunit theta 
P43274 22 38.8 
2.59E-
14 Histone H1.4 
P43275 9 22.1 
7.42E-
14 Histone H1.1 
P43276 12 33.2 
4.27E-
19 Histone H1.5 
P45376 2 10.1 
6.30E-
07 Aldose reductase 





P47753 5 28.0 
5.63E-
13 
F-actin-capping protein subunit 
alpha-1 
P47754 4 21.3 
5.30E-
10 
F-actin-capping protein subunit 
alpha-2 
P47757 6 34.2 
1.39E-
20 
F-actin-capping protein subunit 
beta 





P47911 3 13.5 
2.15E-
10 60S ribosomal protein L6 
P47955 2 51.8 
1.07E-
05 60S acidic ribosomal protein P1 
P47962 2 8.1 
5.55E-
07 60S ribosomal protein L5 





P49722 4 23.5 
1.75E-
12 Proteasome subunit alpha type-2 
P50247 5 16.2 
2.50E-
16 Adenosylhomocysteinase 
P50516 2 8.1 
1.61E-
07 
V-type proton ATPase catalytic 
subunit A 
P50543 2 27.6 
6.47E-
07 Protein S100-A11 
P51150 2 11.1 
3.79E-
06 Ras-related protein Rab-7a 
P51174 2 7.2 
7.53E-
06 
Long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 





P52480 39 60.3 
9.43E-
126 Pyruvate kinase PKM 
P54071 6 16.2 
5.44E-
16 
Isocitrate dehydrogenase [NADP], 
mitochondrial 
P54775 2 15.8 
1.08E-
06 26S protease regulatory subunit 6B 
P56480 3 9.1 
6.33E-
10 
ATP synthase subunit beta, 
mitochondrial 
P57780 9 13.0 
6.19E-
07 Alpha-actinin-4 
P58252 17 31.8 
1.21E-
56 Elongation factor 2 
P59999 3 17.9 
7.49E-
11 
Actin-related protein 2/3 complex 
subunit 4 
P60122 2 6.6 
1.61E-
07 RuvB-like 1 
P60229 2 5.6 
3.26E-
05 
Eukaryotic translation initiation 
factor 3 subunit E 
P60335 3 12.1 
6.45E-
11 Poly(rC)-binding protein 1 
P60710 66 90.1 
1.99E-
80 Actin, cytoplasmic 1 
P60766 5 42.9 
1.72E-
13 
Cell division control protein 42 
homolog 
P60843 6 21.9 
2.81E-
19 Eukaryotic initiation factor 4A-I 
P61161 12 38.6 
7.79E-
38 Actin-related protein 2 














phosphatase PP1-alpha catalytic 
subunit 
P62196 2 8.6 
3.50E-
06 26S protease regulatory subunit 8 
P62242 4 24.5 
1.46E-
11 40S ribosomal protein S8 
P62259 3 20.8 
1.44E-
09 14-3-3 protein epsilon 
P62281 2 17.7 
3.40E-
07 40S ribosomal protein S11 
P62315 2 27.7 
1.61E-
07 
Small nuclear ribonucleoprotein 
Sm D1 
P62317 2 16.1 
1.86E-
06 
Small nuclear ribonucleoprotein 
Sm D2 
P62320 3 31.7 
3.90E-
10 
Small nuclear ribonucleoprotein 
Sm D3 
P62334 3 10.5 
6.45E-
11 
26S protease regulatory subunit 
10B 
P62702 3 8.7 
1.85E-
10 
40S ribosomal protein S4, X 
isoform 
P62806 40 65.0 
1.85E-
127 Histone H4 
P62814 4 11.9 
7.42E-
14 
V-type proton ATPase subunit B, 
brain isoform 
P62827 11 41.7 
9.23E-
34 GTP-binding nuclear protein Ran 
P62855 2 23.5 
9.18E-
06 40S ribosomal protein S26 
P62880 3 12.6 
1.85E-
10 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 
P62889 3 40.9 
6.45E-
11 60S ribosomal protein L30 
P62908 4 21.0 
9.95E-
14 40S ribosomal protein S3 
P62962 5 37.1 
4.76E-
15 Profilin-1 




acetylhydrolase IB subunit alpha 
P63017 19 40.7 
2.11E-
54 Heat shock cognate 71 kDa protein 





P63101 6 31.4 
1.91E-
19 14-3-3 protein zeta/delta 
P63158 4 21.9 
7.97E-
07 High mobility group protein B1 




phosphatase 2A catalytic subunit 
alpha isoform 
P68033 46 68.2 
2.06E-
35 Actin, alpha cardiac muscle 1 
P68040 7 37.2 
1.84E-
23 
Guanine nucleotide-binding protein 
subunit beta-2-like 1 
P68254 2 21.8 
9.12E-
06 14-3-3 protein theta 
P68368 12 36.2 
5.00E-
13 Tubulin alpha-4A chain 
P68372 13 45.2 
4.61E-
07 Tubulin beta-4B chain 
P68373 13 38.3 
2.44E-
16 Tubulin alpha-1C chain 
P68433 28 65.4 
8.73E-
10 Histone H3.1 
P68510 2 17.9 
1.61E-
07 14-3-3 protein eta 
P70168 7 15.5 
9.37E-
22 Importin subunit beta-1 
P70335 2 2.7 
6.30E-
07 Rho-associated protein kinase 1 
P70390 40 13.8 
3.17E-
109 Short stature homeobox protein 2 





P80313 4 11.8 
5.04E-
13 T-complex protein 1 subunit eta 
P80314 2 7.1 
1.32E-
06 T-complex protein 1 subunit beta 
P80315 6 17.8 
1.19E-
20 T-complex protein 1 subunit delta 
P80316 5 19.0 
3.58E-
17 
T-complex protein 1 subunit 
epsilon 
P80317 2 7.0 
1.61E-
07 T-complex protein 1 subunit zeta 




induced protein ig-h3 





P84091 2 9.9 
3.40E-
07 AP-2 complex subunit mu 
P84096 8 53.4 
2.78E-
21 
Rho-related GTP-binding protein 
RhoG 
P84228 33 65.4 
2.08E-
21 Histone H3.2 
P97369 5 23.6 
1.04E-
17 Neutrophil cytosol factor 4 
P97384 7 17.5 
1.44E-
23 Annexin A11 
P99024 14 49.1 
1.85E-
10 Tubulin beta-5 chain 
Q00519 7 10.4 
9.24E-
23 Xanthine dehydrogenase/oxidase 





Q01853 22 41.8 
7.21E-
67 
Transitional endoplasmic reticulum 
ATPase 





Q02357 5 62.8 
2.00E-
14 Ankyrin-1 
Q04750 4 9.3 
4.80E-
12 DNA topoisomerase 1 
Q05144 10 66.7 
8.16E-
31 
Ras-related C3 botulinum toxin 
substrate 2 
Q07076 3 8.9 
7.49E-
11 Annexin A7 
Q07797 2 6.8 
3.50E-
06 Galectin-3-binding protein 
Q3TCJ1 2 7.5 
2.50E-
06 BRISC complex subunit Abro1 
Q3TEA
8 2 4.7 
1.32E-
06 
Heterochromatin protein 1-binding 
protein 3 
Q3THE
2 3 23.8 
1.32E-
09 Myosin regulatory light chain 12B 
Q3TRM
8 14 20.9 
2.20E-
45 Hexokinase-3 
Q3TXS7 2 3.8 
1.94E-
05 
26S proteasome non-ATPase 
regulatory subunit 1 
Q3UGX
2 5 3.5 
8.95E-





2 4 42.1 
2.79E-
12 Calmodulin 
Q3UP87 7 29.1 
8.34E-
23 Neutrophil elastase 
Q3UW5
3 4 7.3 
1.20E-
12 Protein Niban 
Q3UZZ




4 2 5.1 
3.34E-
06 Olfactomedin-like protein 2B 
Q571I9 5 10.3 
8.53E-
17 
Aldehyde dehydrogenase family 16 
member A1 
Q5SQX





Q5SS00 2 0.3 
2.45E-
07 
DBF4-type zinc finger-containing 
protein 2 homolog 
Q5SXR
6 32 29.7 
1.08E-
98 Clathrin heavy chain 1 
Q60605 7 51.0 
5.50E-
23 Myosin light polypeptide 6 
Q60692 2 10.9 
4.61E-
07 Proteasome subunit beta type-6 
Q61081 2 10.0 
1.61E-
07 Hsp90 co-chaperone Cdc37 
Q61096 2 10.2 
4.61E-
07 Myeloblastin 
Q61171 5 34.8 
8.20E-
15 Peroxiredoxin-2 
Q61210 7 12.9 
2.44E-
22 
Rho guanine nucleotide exchange 
factor 1 
Q61233 22 49.6 
1.41E-
72 Plastin-2 
Q61316 2 3.6 
8.46E-
07 Heat shock 70 kDa protein 4 
Q61508 2 6.5 
1.81E-
06 Extracellular matrix protein 1 
Q61598 4 18.1 
2.77E-
13 
Rab GDP dissociation inhibitor 
beta 
Q61599 2 23.5 
1.61E-
07 Rho GDP-dissociation inhibitor 2 
Q61646 7 33.1 
2.94E-
20 Haptoglobin 
Q61656 3 6.4 
5.30E-
10 










Q61990 2 8.3 
3.20E-
07 Poly(rC)-binding protein 2 
Q62465 3 6.9 
2.23E-
09 
Synaptic vesicle membrane protein 
VAT-1 homolog 
Q63844 9 29.2 
6.58E-
20 Mitogen-activated protein kinase 3 
Q64514 3 5.0 
1.19E-
08 Tripeptidyl-peptidase 2 
Q64522 43 60.8 
1.33E-
27 Histone H2A type 2-B 
Q64727 5 9.3 
1.36E-
16 Vinculin 





exchanger 1 protein 
Q6GSS7 41 70.8 
6.45E-
11 Histone H2A type 2-A 
Q6IRU2 2 10.9 
1.25E-
05 Tropomyosin alpha-4 chain 
Q6P069 4 27.9 
4.91E-
13 Sorcin 
Q6P4T2 2 2.1 
1.32E-
06 
U5 small nuclear ribonucleoprotein 
200 kDa helicase 
Q6P5F9 5 7.7 
6.21E-
16 Exportin-1 















binding protein 4 
Q6PHN
9 2 12.4 
1.61E-
07 Ras-related protein Rab-35 




dissociated protein 1 
Q6ZQA
0 4 2.8 
7.92E-
14 Neurobeachin-like protein 2 
Q6ZWR








phosphatase 2A 65 kDa regulatory 








containing protein 1 




associated 1-like protein 2 






9 2 3.8 
2.65E-
06 Transportin-1 
Q8BFZ3 29 49.2 
1.54E-
16 Beta-actin-like protein 2 
Q8BG32 6 18.2 
1.35E-
18 
26S proteasome non-ATPase 
regulatory subunit 11 
Q8BJY1 2 6.3 
1.61E-
07 
26S proteasome non-ATPase 
regulatory subunit 5 








9 3 12.0 
1.85E-
10 26S protease regulatory subunit 7 
Q8BWT





Q8C147 5 13.7 
2.74E-
15 Dedicator of cytokinesis protein 8 











0 5 12.4 
1.02E-
05 Core histone macro-H2A.2 
Q8CG29 3 4.4 
6.45E-
11 Myosin IF 
Q8CGP
1 25 74.6 
7.07E-
13 Histone H2B type 1-K 
Q8CGP
4 25 58.9 
3.76E-
13 Histone H2A 
Q8CIE6 5 5.1 
2.07E-
17 Coatomer subunit alpha 






Q8CIZ8 9 36.6 
1.41E-




Q8JZQ9 2 5.1 
1.22E-
06 
Eukaryotic translation initiation 
factor 3 subunit B 
Q8K0E8 14 39.1 
2.62E-
45 Fibrinogen beta chain 
Q8K1B8 19 40.6 
3.07E-
60 Fermitin family homolog 3 
Q8K1X
4 3 5.4 
2.13E-
09 NCK associated protein 1 like 
Q8K426 2 23.1 
1.61E-
07 Myeloid cysteine-rich protein 




1 4 11.7 
7.42E-
14 
Eukaryotic translation initiation 
factor 3 subunit L 
Q8R010 2 12.8 
9.17E-
07 
Aminoacyl tRNA synthase 
complex-interacting 
multifunctional protein 2 





Q8R1B4 3 2.9 
1.06E-
09 
Eukaryotic translation initiation 
factor 3 subunit C 
Q8R1Q8 3 12.6 
2.73E-
09 
Cytoplasmic dynein 1 light 
intermediate chain 1 
Q8R2S8 11 22.4 
7.06E-
37 CD177 antigen 
Q8VCI0 2 6.0 
2.89E-
05 Phospholipase B-like 1 
Q8VCM
7 12 40.8 
6.15E-
39 Fibrinogen gamma chain 
Q8VCT
3 10 20.6 
1.94E-
32 Aminopeptidase B 
Q8VDD




4 3 6.2 
5.30E-
10 
26S proteasome non-ATPase 
regulatory subunit 2 
Q8VDP
4 2 5.1 
2.65E-
06 
DBIRD complex subunit 
KIAA1967 homolog 
Q8VDW
0 2 11.0 
1.32E-
06 
ATP-dependent RNA helicase 
DDX39A 
Q8VEK






7 3 13.9 
1.13E-




Q8VIJ6 2 7.9 
3.50E-
06 
Splicing factor, proline- and 
glutamine-rich 
Q91V92 8 11.4 
6.70E-
28 ATP-citrate synthase 
Q91VI7 3 12.3 
5.10E-
09 Ribonuclease inhibitor 





Q91Z50 2 8.2 
4.61E-
07 Flap endonuclease 1 
Q921G6 3 7.8 
1.36E-
10 
Leucine-rich repeat and calponin 
homology domain-containing 
protein 4 
Q921I1 9 20.1 
1.22E-
28 Serotransferrin 
Q921M3 3 5.8 
1.83E-
09 Splicing factor 3B subunit 3 










Q922U2 2 3.8 
2.27E-
06 Keratin, type II cytoskeletal 5 
Q93092 4 14.5 
1.01E-
13 Transaldolase 
Q99J77 2 12.8 
1.61E-
07 
N-acetylneuraminic acid synthase 
(Sialic acid synthase) 
Q99JI4 3 10.3 
2.71E-
10 
26S proteasome non-ATPase 
regulatory subunit 6 
Q99JI6 2 12.5 
4.61E-
07 Ras-related protein Rap-1b 
Q99JY9 13 51.9 
1.66E-
42 Actin-related protein 3 





Q99KE1 7 20.7 
2.61E-
21 
NAD-dependent malic enzyme, 
mitochondrial 
Q99KI0 2 4.1 
4.92E-
07 Aconitate hydratase, mitochondrial 
Q99KK





Q99KP6 2 8.1 
1.61E-




Q99LB4 2 7.7 
8.96E-
05 
Capping protein (Actin filament), 
gelsolin-like 
Q99LC5 2 12.9 
1.61E-
07 
Electron transfer flavoprotein 
subunit alpha, mitochondrial 
Q99MK
8 5 11.0 
6.85E-
16 Beta-adrenergic receptor kinase 1 
Q99NB9 2 2.8 
2.74E-
05 Splicing factor 3B subunit 1 






8 5 32.8 
2.17E-
16 14-3-3 protein beta/alpha 
Q9CVB
6 4 24.3 
1.46E-
12 
Actin-related protein 2/3 complex 
subunit 2 
Q9CW0
3 2 2.5 
1.07E-
05 
Structural maintenance of 
chromosomes protein 3 
Q9CWJ
9 5 14.9 
1.49E-
15 
Bifunctional purine biosynthesis 
protein PURH 
Q9CZN
7 3 13.5 
1.71E-
08 Serine hydroxymethyltransferase 
Q9CZU
6 5 23.1 
2.98E-
17 Citrate synthase, mitochondrial 





Q9D154 9 36.9 
1.38E-
26 Leukocyte elastase inhibitor A 
Q9D2V




0 9 30.2 
8.55E-
29 Elongation factor 1-gamma 






3 5 9.0 
2.16E-
07 AP-2 complex subunit beta 
Q9DBJ1 7 32.7 
6.66E-
22 Phosphoglycerate mutase 1 
Q9DCD






4 2 10.0 
4.61E-
07 
Eukaryotic translation initiation 
factor 3 subunit F 
Q9EPU0 3 4.6 
3.22E-
09 Regulator of nonsense transcripts 1 
Q9EQH
3 8 16.5 
7.97E-
26 






5 15 28.3 
1.36E-
44 Major vault protein 
Q9ERK
4 3 5.7 
4.35E-
10 Exportin-2 
Q9ESX5 2 7.1 
1.08E-
06 
H/ACA ribonucleoprotein complex 
subunit 4 
Q9ET01 32 46.4 
2.49E-
101 
Glycogen phosphorylase, liver 
form 
Q9JHK5 2 8.0 
4.61E-
07 Pleckstrin 
Q9JHU4 22 8.4 
1.53E-
66 
Cytoplasmic dynein 1 heavy chain 
1 





Q9JIF7 4 7.6 
5.00E-
13 Coatomer subunit beta 
Q9JJ28 5 8.2 
2.26E-
16 Protein flightless-1 homolog 
Q9JKF1 24 22.9 
1.92E-
77 
Ras GTPase-activating-like protein 
IQGAP1 
Q9JKR6 2 4.0 
6.98E-
07 Hypoxia up-regulated protein 1 
Q9JL26 2 3.0 
1.32E-
06 Formin-like protein 1 
Q9JM76 5 34.3 
5.03E-
16 
Actin-related protein 2/3 complex 
subunit 3 
Q9QUI0 3 24.9 
1.07E-
09 Transforming protein RhoA 
Q9QUM
0 7 12.6 
7.51E-
21 Integrin alpha-IIb 
Q9QUM
9 4 17.9 
2.59E-
14 Proteasome subunit alpha type-6 
Q9QWK
4 2 6.5 
1.04E-
05 CD5 antigen-like 
Q9QXK
3 4 9.3 
1.03E-
12 Coatomer subunit gamma-2 
Q9QZD
9 2 5.5 
1.32E-
06 
Eukaryotic translation initiation 
factor 3 subunit I 
Q9QZQ
8 23 48.8 
9.49E-
32 Core histone macro-H2A.1 
Q9R062 7 34.8 
2.29E-
21 Glycogenin-1 






Q9R0P5 4 32.7 
7.42E-
14 Destrin 
Q9R111 5 20.9 
1.03E-
15 Guanine deaminase 
Q9R1P0 3 21.5 
9.16E-
10 Proteasome subunit alpha type-4 
Q9R1P3 3 21.4 
1.85E-
10 Proteasome subunit beta type-2 
Q9R1P4 3 14.4 
1.85E-
10 Proteasome subunit alpha type-1 
Q9WU7
8 11 23.1 
1.14E-
34 
Programmed cell death 6-
interacting protein 
Q9WUA
2 2 4.2 
3.20E-
07 
Phenylalanine--tRNA ligase beta 
subunit 
Q9WU




2 9 36.3 
5.35E-
31 
Actin-related protein 2/3 complex 
subunit 1B 
Q9WVJ
2 3 12.2 
2.09E-
08 
26S proteasome non-ATPase 
regulatory subunit 13 
Q9WVK
4 9 28.7 
6.41E-
28 EH domain-containing protein 1 
Q9Z0N1 2 6.8 
1.91E-
06 
Eukaryotic translation initiation 
factor 2 subunit 3, X-linked 
Q9Z0P5 2 9.8 
5.67E-
07 Twinfilin-2 
Q9Z126 4 46.7 
7.42E-
14 Platelet factor 4 
Q9Z183 4 11.7 
1.77E-
12 Protein-arginine deiminase type-4 
Q9Z1E4 4 11.4 
2.59E-
14 Glycogen [starch] synthase, muscle 
Q9Z1Q5 10 47.7 
2.04E-
33 
Chloride intracellular channel 
protein 1 
Q9Z1Q9 12 20.0 
1.38E-
36 Valine--tRNA ligase 
Q9Z2L7 2 11.0 
4.49E-
07 Cytokine receptor-like factor 3 
Q9Z2U0 5 30.6 
1.24E-
15 Proteasome subunit alpha type-7 
Q9Z2U1 3 24.9 
1.14E-





Appendix Table 2: Proteins identified in MDSC-derived exosomes that have not 
previously been reported in ExoCarta, EVpedia, or Vesiclepedia. 
Protein Protein Name 
D3Z6Q9 Bridging integrator 2 
E9Q0F0 Protein Krt78 
E9QQ35 
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing 
subunit gamma 
O70138 Neutrophil collagenase 
P01794 Ig heavy chain V region HPCG14 
P01872 Ig mu chain C region secreted form 
P08032 Spectrin alpha chain, erythrocytic 1 
Q00612 Glucose-6-phosphate 1-dehydrogenase X 
Q69ZK0 
Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac 
exchanger 1 protein 
Q8K426 Myeloid cysteine-rich protein 
Q99MK8 Beta-adrenergic receptor kinase 1 
 
 
Appendix Table 3: Peptide and protein identifications of ubiquitinated proteins in 
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Appendix Figure 1: Annotated tandem mass spectra for all single peptide 
identifications containing a glycinylglycine ubiquitin remnant.  B-type (blue) and y-
type ions (red) are labeled to the corresponding peaks in the tandem mass spectra 
shown. 




b. E0CYH9 Carboxyl-terminal PDZ ligand of neuronic nitric oxide synthase 







c. Q6P925 Cysteine-rich perinuclear theca 4 FDR 5.100E-2 


















































































































r. Q6ZPJ3 Ubiquitin-conjugating enzyme E2 O FDR 5.09E-2 
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